timestamp,url,text
2025-01-02 09:58:00+00:00,https://www.globenewswire.com/news-release/2025/01/02/3003380/28124/en/Eosinophilic-Esophagitis-Market-Insight-Epidemiology-and-Market-Forecast-to-2034.html,"Eosinophilic Esophagitis Market Insight, Epidemiology and Market Forecast to 2034 The report provides an in-depth analysis of the Eosinophilic Esophagitis market, including epidemiology, current treatment practices, emerging drugs, and market trends across the United States, EU4, the United Kingdom, and Japan. The market is expected to grow during the forecast period, driven by the development of novel treatments and the establishment of comprehensive guidelines."
2025-01-02 12:30:00+00:00,https://www.fool.com/investing/2025/01/02/got-5000-these-3-stocks-are-absurdly-cheap-buys/?source=iedfolrf0000001,"Got $5,000? These 3 Stocks Are Absurdly Cheap Buys Heading Into 2025 The article recommends three stocks to invest $5,000 in: Pfizer, L3Harris Technologies, and Dell. Pfizer is trading at a discount, L3Harris could benefit from increased defense spending, and Dell could see a boost from AI-capable PCs."
2025-01-03 10:21:00+00:00,https://www.fool.com/investing/2025/01/03/3-ultra-high-yield-dividend-stocks-buy-in-2025/?source=iedfolrf0000001,"3 Ultra-High-Yield Dividend Stocks That Are Screaming Buys in 2025 The article highlights three high-yield dividend stocks that are considered undervalued and attractive investments for 2025: Ford Motor Company, PennantPark Floating Rate Capital, and Pfizer. The companies are analyzed based on their financial performance, growth prospects, and valuation."
2025-01-03 15:39:00+00:00,https://www.globenewswire.com/news-release/2025/01/03/3004072/28124/en/Big-Pharma-Partnering-Terms-and-Agreements-Analysis-Report-2024-with-Directory-of-Over-2-000-Deals-Signed-Since-2020.html,"Big Pharma Partnering Terms and Agreements Analysis Report 2024 with Directory of Over 2,000 Deals Signed Since 2020 The report provides a detailed analysis of over 2,000 Big Pharma deals signed since 2020, including trends, key players, deal financials, and contract details. It offers insights into how and why companies enter these partnerships."
2025-01-03 15:46:00+00:00,https://www.globenewswire.com/news-release/2025/01/03/3004075/0/en/AUA-Partners-with-Pfizer-to-Launch-1-5-Million-RFP-to-Advance-Care-for-Patients-with-Advanced-Prostate-Cancer.html,AUA Partners with Pfizer to Launch $1.5 Million RFP to Advance Care for Patients with Advanced Prostate Cancer The American Urological Association (AUA) and Pfizer have partnered to offer $1.5 million in grant funding for projects aimed at improving care for patients with advanced prostate cancer. The initiative seeks to address critical gaps in patient care and support novel quality improvement solutions.
2025-01-03 17:16:00+00:00,https://www.fool.com/investing/2025/01/03/should-you-buy-pfizer-stock-right-now-in-2025/?source=iedfolrf0000001,"Should You Buy Pfizer Stock Right Now in 2025? Pfizer is an interesting healthcare company with excellent prospects for cash flow growth, according to the article."
2025-01-04 13:35:00+00:00,https://www.fool.com/investing/2025/01/04/time-to-dump-or-double-up-on-schd/?source=iedfolrf0000001,"Time to Dump or Double Up on SCHD? The article discusses the Schwab US Dividend Equity ETF (SCHD) and whether investors should buy, sell, or hold the ETF. It also looks at the top 10 holdings of the ETF, including Pfizer, Coca-Cola, and AbbVie."
2025-01-05 08:30:00+00:00,https://www.fool.com/investing/2025/01/05/is-pfizer-stock-undervalued-at-current-prices/?source=iedfolrf0000001,Is Pfizer Stock Undervalued at Current Prices? The article discusses the valuation and prospects of Pfizer (PFE) stock. It also mentions that 360 stocks in the S&P 500 underperformed the benchmark's 2024 gain of 24% and provides recommendations for two high-yielding S&P 500 stocks to buy in 2025.
2025-01-06 09:42:00+00:00,https://www.fool.com/investing/2025/01/06/25-top-dividend-stocks-to-buy-and-hold-in-2025/?source=iedfolrf0000001,"25 Top Dividend Stocks to Buy and Hold in 2025 The article discusses 25 top dividend stocks to buy and hold in 2025, including companies from the financial, energy, healthcare, utility, and real estate sectors. It highlights the potential benefits of these stocks, such as attractive dividend yields, strong balance sheets, and promising growth prospects."
2025-01-07 09:15:00+00:00,https://www.fool.com/investing/2025/01/07/buffett-warning-to-wall-street-what-to-do-2025/?source=iedfolrf0000001,"Warren Buffett's Warning to Wall Street Reached Deafening Proportions in 2024. Here's What to Do as 2025 Gets Started. Warren Buffett has been a net seller of stocks and is holding a record level of cash, signaling caution about the market's valuation. The article suggests diversifying investments, focusing on long-term potential, and selectively buying undervalued stocks to position for success in 2025."
2025-01-07 10:46:00+00:00,https://www.fool.com/investing/2025/01/07/investing-50000-in-each-of-these-5-stocks-could-ma/?source=iedfolrf0000001,"Investing $50,000 in Each of These 5 Stocks Could Make You Nearly $17,500 in Passive Income in 2025 Investing $50,000 in each of 5 high-yield dividend stocks - Ares Capital, Energy Transfer, Enterprise Products Partners, Pfizer, and Verizon - could generate around $17,500 in passive income in 2025."
2025-01-08 10:48:00+00:00,https://www.fool.com/investing/2025/01/08/prediction-these-could-be-the-best-performing-valu/?source=iedfolrf0000001,"Prediction: These Could Be the Best-Performing Value Stocks Through 2030 The article discusses three value stocks that could be the best-performing through 2030: D.R. Horton, Moderna, and Pfizer. It highlights their attractive valuations, growth prospects, and potential to outperform the market."
2025-01-09 19:12:20+00:00,https://www.benzinga.com/general/biotech/25/01/42901177/obesity-treatments-ma-activity-to-take-center-stage-during-upcoming-jpm-healthcare-conference,"Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference The upcoming JPM Healthcare Conference is expected to focus on obesity treatments and M&A activity in the biopharma sector. Analysts project key drug launches, such as Bristol-Myers Squibb's Cobenfy, to fuel growth in 2025, while sentiment remains mixed for the US Large Cap BioPharma group."
2025-01-10 10:58:00+00:00,https://www.globenewswire.com/news-release/2025/01/10/3007486/28124/en/Nicotine-Replacement-Therapies-Market-Forecast-to-Reach-7-52-Billion-by-2032-Growing-Shift-Towards-Personalised-Nicotine-Replacement-Therapies.html,"Nicotine Replacement Therapies Market Forecast to Reach $7.52 Billion by 2032: Growing Shift Towards Personalised Nicotine Replacement Therapies The global nicotine replacement therapy market is expected to grow at a CAGR of 9.3% from 2024 to 2032, driven by rising health awareness, government initiatives, and technological advancements. Key players in the market include GSK, Pfizer, Johnson & Johnson, and others."
2025-01-10 14:35:00+00:00,https://www.globenewswire.com/news-release/2025/01/10/3007777/28124/en/Diabetic-Retinopathy-Global-Clinical-Trials-Review-2024-Region-country-G7-E7-phase-trial-status-End-points-Status-and-Sponsor-Type.html,"Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type The report provides an overview of the global clinical trials landscape for diabetic retinopathy, including details on trial numbers, enrollment, and status across different regions, countries, phases, and sponsor types. It also highlights prominent drugs and companies involved in these trials."
2025-01-13 09:46:00+00:00,https://www.globenewswire.com/news-release/2025/01/13/3008183/28124/en/Ophthalmic-Drugs-Global-Market-Report-2025-Innovations-in-Retinal-Disorders-Glaucoma-Drive-Global-Ophthalmic-Medicines-Surge.html,"Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge The global ophthalmic drugs market is expected to surpass $35 billion in 2025, driven by rising incidences of eye-related conditions and a strong pipeline of new drugs. However, side effects of topical ophthalmic drugs may limit market growth, necessitating a comprehensive strategy to address safety concerns."
2025-01-13 10:05:00+00:00,https://www.fool.com/investing/2025/01/13/9-dividend-etfs-to-buy-with-200-and-hold-forever/?source=iedfolrf0000001,"9 Dividend ETFs to Buy With $200 and Hold Forever Dividends are powerful wealth builders, and investing in dividend-paying stocks or exchange-traded funds (ETFs) can be an effective way to grow your portfolio over time. The article provides examples of dividend-paying companies and ETFs, and discusses the benefits of dividend investing."
2025-01-13 10:10:00+00:00,https://www.fool.com/investing/2025/01/13/investing-5000-just-once-in-these-3-ultra-high-yie/?source=iedfolrf0000001,"Investing $5,000 Just Once in These 3 Ultra-High-Yielding Stocks Could Earn You $320 in Passive Income Every Year The article discusses three high-yielding stocks - Verizon, Pfizer, and Ford - that could provide $320 in annual passive income if invested in equally with $5,000. It analyzes the companies' ability to maintain and grow their dividends."
2025-01-14 19:10:20+00:00,https://www.benzinga.com/25/01/42986202/pfizer-eyes-20-billion-revenue-from-acquisitions-amid-patent-cliff-challenges,"Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges Pfizer aims to offset $17-18 billion in revenue losses from 2026-2028 through acquisitions, which are projected to drive $20 billion in revenue by 2030. The company has also achieved $4 billion in cost savings and announced an additional $1.5 billion in margin improvements."
2025-01-15 10:10:00+00:00,https://www.fool.com/investing/2025/01/15/got-200-2-dividend-stocks-to-buy-and-hold-forever/?source=iedfolrf0000001,"Got $200? 2 Dividend Stocks to Buy and Hold Forever Pfizer and Johnson & Johnson are two pharmaceutical industry stalwarts with long histories, generous dividends, and solid growth prospects. Despite recent challenges, Pfizer is reinventing itself with a focus on oncology, while Johnson & Johnson's diversification and consistent dividend growth make it a timeless investment option."
2025-01-16 13:10:00+00:00,https://www.fool.com/investing/2025/01/16/is-moderna-a-bad-news-buy-for-2025/?source=iedfolrf0000001,"Is Moderna a Bad-News Buy for 2025? Moderna, a biotech company, has faced challenges with declining demand for its COVID-19 vaccine and lower-than-expected revenue from its RSV vaccine. However, the company plans to launch 10 new products in the next few years, which could lead to significant growth. The article discusses the pros and cons of investing in Moderna at this time."
2025-01-17 17:15:20+00:00,https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations,"Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations The U.S. Department of Health and Human Services has selected 15 additional drugs, including Ozempic and Wegovy, for price negotiations under Medicare Part D. The negotiations, mandated by the Inflation Reduction Act, aim to reduce prescription drug costs and out-of-pocket expenses for Medicare beneficiaries."
2025-01-18 10:42:00+00:00,https://www.fool.com/investing/2025/01/18/bought-ultra-high-yield-dividend-stocks/?source=iedfolrf0000001,"Why I Just Bought These 3 Ultra-High-Yield Dividend Stocks The article discusses three high-yield dividend stocks that the author recently bought: Dominion Energy, Pfizer, and United Parcel Service. The author provides reasons for investing in these stocks, including their attractive dividend yields and growth prospects."
2025-01-19 10:51:00+00:00,https://www.fool.com/investing/2025/01/19/the-smartest-dividend-stocks-to-buy-with-100-right/?source=iedfolrf0000001,"The Smartest Dividend Stocks to Buy With $100 Right Now The article discusses two dividend stocks, Ares Capital and Enterprise Products Partners, that offer high yields and are recommended as smart investments for income-seeking investors. It also mentions Pfizer as a third potential investment option."
2025-01-20 09:52:00+00:00,https://www.fool.com/investing/2025/01/20/ultra-high-yield-dividend-stocks-passive-income/?source=iedfolrf0000001,"Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,000 in Passive Income in 2025 Investing $10,000 in each of 5 high-yield dividend stocks could generate over $3,000 in passive income in 2025. The stocks mentioned are Enbridge, Pfizer, Realty Income, United Parcel Service, and Verizon Communications."
2025-01-20 12:45:00+00:00,https://www.fool.com/investing/2025/01/20/3-subtle-investing-mistakes-i-wont-repeat-in-2025/?source=iedfolrf0000001,"3 Subtle Investing Mistakes I Won't Repeat in 2025 And Beyond The article discusses three investing mistakes the author made in 2024, including failing to update his investment thesis on Pfizer, not doing due diligence on Costco's new CEO, and assuming Apple's growth would continue indefinitely. The author shares lessons learned to help readers avoid similar mistakes."
2025-01-20 14:55:00+00:00,https://www.globenewswire.com/news-release/2025/01/20/3012153/0/en/Pain-Management-Therapeutics-Market-Is-Expected-To-Reach-Revenue-Of-USD-120-7-Bn-By-2033-At-3-9-CAGR-Dimension-Market-Research.html,"Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. The global pain management therapeutics market is expected to grow from $85.2 billion in 2024 to $120.7 billion by 2033, driven by the increasing prevalence of chronic pain conditions and the development of non-opioid therapies."
2025-01-22 11:16:00+00:00,https://www.fool.com/investing/2025/01/22/is-pfizer-stock-a-buy/?source=iedfolrf0000001,"Is Pfizer Stock a Buy? Pfizer, a pharmaceutical giant, has seen its stock price decline after the pandemic-driven boost from its COVID-19 vaccine and treatment. However, the company's non-COVID growth is starting to drive the business again, and its high dividend yield of 6.3% may present an opportunity for investors."
2025-01-23 09:15:00+00:00,https://www.fool.com/investing/2025/01/23/my-top-5-stocks-to-buy-in-early-2025/?source=iedfolrf0000001,"My Top 5 Stocks to Buy in Early 2025 The article recommends five healthcare stocks for long-term investment: Pfizer, Eli Lilly, Abbott Laboratories, Intuitive Surgical, and CRISPR Therapeutics. These companies offer a mix of growth and security, with diversified portfolios, innovative products, and strong financial positions."
2025-01-23 12:30:00+00:00,https://www.fool.com/investing/2025/01/23/can-this-beaten-down-stock-bounce-back-in-2025/?source=iedfolrf0000001,"Can This Beaten-Down Stock Bounce Back in 2025? Pfizer's financial results have fallen off a cliff, and its stock price has suffered. The company has made progress, but nothing has stopped the bleeding yet. Pfizer's revenue guidance for 2025 is not particularly exciting, but its adjusted earnings per share are expected to grow. The company's work in the weight loss market could positively affect its stock performance, but it faces competition from other drugmakers. Pfizer may not perform well this year, but it has been setting up a foundation for the future, and its strong dividend makes it attractive for long-term investors."
2025-01-25 09:51:00+00:00,https://www.fool.com/investing/2025/01/25/want-decades-of-passive-income-3-stocks-to-buy-now/?source=iedfolrf0000001,"Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. The article discusses three companies with impressive dividend track records: Chevron, Pfizer, and Verizon Communications. It highlights their long-term dividend growth, current dividend yields, and future growth prospects."
2025-01-25 10:46:00+00:00,https://www.fool.com/investing/2025/01/25/got-100-this-top-dividend-etf-is-a-no-brainer-buy/?source=iedfolrf0000001,"Got $100? This Top Dividend ETF Is a No-Brainer Buy Right Now. The article discusses the benefits of investing in dividend stocks, particularly through the Schwab U.S. Dividend Equity ETF (SCHD). It highlights the superior returns of dividend-growing stocks and the ETF's focus on high-quality, dividend-paying companies."
2025-01-25 12:45:00+00:00,https://www.fool.com/investing/2025/01/25/move-over-mounjaro-eli-lilly-has-another-blockbust/?source=iedfolrf0000001,"Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It. Eli Lilly's oncology business, particularly its drug Verzenio, is emerging as a significant growth opportunity for the company, overshadowed by the focus on its weight loss treatments Mounjaro and Zepbound."
2025-01-26 14:30:00+00:00,https://www.fool.com/investing/2025/01/26/have-500-2-high-yield-dividend-stocks-to-buy-right/?source=iedfolrf0000001,"Have $500? 2 High-Yield Dividend Stocks to Buy Right Now The article discusses two dividend stocks, Pfizer and Realty Income, that could be good investments for long-term investors with $500 to put to work. Pfizer's dividend yield is robust at 6.6%, and the company is expected to bring numerous blockbuster drugs to market in the coming years. Realty Income is a REIT with a 5.8% dividend yield and a history of paying dividends for over 55 years."
2025-01-27 15:49:00+00:00,https://www.globenewswire.com/news-release/2025/01/27/3015778/28124/en/Biological-Drugs-Strategic-Research-Report-2024-2030-Profiles-of-45-Players-Including-Abbott-Laboratories-Amgen-Baxter-Biogen-BMS-Eli-Lilly-and-Co-GSK-Merck-Novartis-and-Pfizer.html,"Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer The global market for Biological Drugs is projected to reach US$634.4 Billion by 2030, growing at a CAGR of 9.1% from 2023 to 2030. The report provides insights into market trends, drivers, and forecasts, as well as profiles of major players in the industry."
2025-01-28 11:15:00+00:00,https://www.fool.com/investing/2025/01/28/i-own-4-high-yield-dividend-stocks-heres-why-i-own/?source=iedfolrf0000001,"I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One. The article discusses four high-yield dividend stocks that the author believes are compelling investments for the long term, including AbbVie, HSBC Holdings, Pfizer, and Philip Morris International."
2025-01-29 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/01/29/3017501/0/en/BRAF-Inhibitors-Market-to-Register-Incremental-Growth-During-the-Study-Period-2020-2034-DelveInsight.html,"BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight The BRAF inhibitor market is expected to grow significantly due to the increasing number of cancer patients, rise in biomarker testing, and ongoing research and development of next-generation BRAF-targeting therapies."
2025-01-31 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/01/31/3018829/32656/en/Recombinant-Chemicals-Market-to-Reach-US-6-7-Bn-by-2034-Driven-by-Rising-Demand-for-Protein-Based-Vaccines-Genetic-Disorder-Treatments-TMR-Analysis.html,"Recombinant Chemicals Market to Reach US$ 6.7 Bn by 2034, Driven by Rising Demand for Protein-Based Vaccines & Genetic Disorder Treatments – TMR Analysis The recombinant chemicals market is experiencing significant growth, driven by the increasing demand for recombinant protein vaccines and advancements in genetic disorder treatments. Leading players like Genentech, Amgen, Pfizer, and Merck are at the forefront of innovation, continuously enhancing recombinant DNA production techniques to meet the growing demand."
2025-02-03 09:52:00+00:00,https://www.globenewswire.com/news-release/2025/02/03/3019270/28124/en/Orphan-Designated-Drugs-Market-Analysis-Key-Trends-Players-and-Forecasts-for-Future-Growth.html,"Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth The report examines the trends shaping the orphan designated drugs market, including healthcare, technology, macroeconomic, and regulatory factors. It provides insights into leading players and future challengers across the value chain, as well as key drugs and markets."
2025-02-03 15:34:16+00:00,https://www.benzinga.com/25/02/43438158/pfizers-newly-approved-braftovi-combination-regimen-for-colorectal-cancer-shows-improved-survival-in-late-stage-s,"Pfizer Trial For Colorectal Cancer Treatment Shows Improved Survival In Late-Stage Study Pfizer's Phase 3 BREAKWATER trial showed its Braftovi combination significantly improved progression-free survival and overall survival in metastatic colorectal cancer with BRAF V600E mutation, compared to chemotherapy."
2025-02-04 10:06:00+00:00,https://www.fool.com/investing/2025/02/04/2-ultra-high-yield-dividend-stocks-buy-in-february/?source=iedfolrf0000001,"2 Ultra-High-Yield Dividend Stocks That Are No-Brainer Buys in February The article highlights two high-yield dividend stocks, Pfizer and Realty Income, as attractive investment opportunities. Pfizer's strong drug portfolio and Realty Income's defensive real estate portfolio make them compelling choices for income-seeking investors."
2025-02-04 16:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/04/3020568/28124/en/Aplastic-Anemia-Global-Clinical-Trials-Review-2024-Now-Available.html,"Aplastic Anemia Global Clinical Trials Review 2024 | Now Available The report provides an overview of clinical trials on Aplastic Anemia, including trial numbers, enrollment, and prominent drugs in progress. It aims to assist in formulating business strategies and identifying opportunities in the global therapeutics market."
2025-02-06 09:51:00+00:00,https://www.globenewswire.com/news-release/2025/02/06/3021793/28124/en/Respiratory-Disease-Vaccines-Market-Research-Report-2025-Analysis-and-Forecast-2020-2030-Featuring-GSK-Johnson-Johnson-Services-Pfizer-Sanofi-Serum-Institute-of-India-SINOVAC-Biote.html,"Respiratory Disease Vaccines Market Research Report 2025: Analysis and Forecast (2020-2030) Featuring GSK, Johnson & Johnson Services, Pfizer, Sanofi, Serum Institute of India, SINOVAC Biotech & More The global respiratory disease vaccine market is expected to grow from $94.6 billion in 2024 to $101.56 billion by 2030, driven by factors such as the increasing prevalence of respiratory diseases, the aging population, and government vaccine mandates and recommendations."
2025-02-07 16:39:00+00:00,https://www.globenewswire.com/news-release/2025/02/07/3022898/32656/en/Paresthesia-Treatment-Market-Outlook-USD-8-0-Billion-by-2034-Growing-with-an-Aging-Population-and-Rising-Healthcare-Expenditures-Analysis-by-TMR.html,"Paresthesia Treatment Market Outlook: USD 8.0 Billion by 2034, Growing with an Aging Population and Rising Healthcare Expenditures | Analysis by TMR The global paresthesia treatment market is expected to grow to $8.0 billion by 2034, driven by the increasing prevalence of neurological disorders, advancements in medical technology, and rising healthcare expenditures."
2025-02-09 10:43:00+00:00,https://www.fool.com/investing/2025/02/09/3-dividend-stocks-to-double-up-on-right-now/?source=iedfolrf0000001,"3 Dividend Stocks to Double Up on Right Now The article discusses the strong performance and growth prospects of AbbVie, Enbridge, and Pfizer, highlighting their impressive dividends and ability to overcome potential challenges."
2025-02-13 10:06:00+00:00,https://www.fool.com/investing/2025/02/13/3-ultra-high-yield-dividend-stocks-buy-right-now/?source=iedfolrf0000001,"3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now The article highlights three high-yield dividend stocks that patient investors can buy with $300: Pfizer, Verizon, and Ford. These stocks have yields ranging from 6.5% to 6.7% and are considered historically cheap, making them attractive for long-term income-seeking investors."
2025-02-13 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/13/3025919/0/en/Respiratory-Syncytial-Virus-Therapeutics-Market-to-Hit-USD-4-64-Billion-by-2032-Growing-at-a-14-5-CAGR-SNS-Insider.html,"Respiratory Syncytial Virus Therapeutics Market to Hit USD 4.64 Billion by 2032, Growing at a 14.5% CAGR – SNS Insider The global Respiratory Syncytial Virus (RSV) Therapeutics market is expected to grow significantly, driven by increased awareness of RSV's health risks and the development of advanced treatment options. Key players in the market include Moderna, Pfizer, GlaxoSmithKline, AstraZeneca, Sanofi, Merck, Johnson & Johnson, Novavax, Bavarian Nordic, and Alnylam Pharmaceuticals."
2025-02-14 16:48:07+00:00,https://www.benzinga.com/25/02/43737281/pfizers-talzennaxtandi-combo-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer,"Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer Pfizer's Talzenna (talazoparib) in combination with Xtandi (enzalutamide) demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to Xtandi alone in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations."
2025-02-18 09:35:00+00:00,https://www.fool.com/investing/2025/02/18/3-things-you-need-to-know-if-you-buy-pfizer-today/?source=iedfolrf0000001,"3 Things You Need to Know If You Buy Pfizer Today Pfizer's revenue soared during the pandemic due to its COVID-19 vaccine and treatment, but demand has since declined. While the company is preparing for patent expirations and launching new products, it may take time for Pfizer's growth to fully rebound. However, the stock's current valuation makes it an attractive buy for patient investors."
2025-02-18 11:15:00+00:00,https://www.fool.com/investing/2025/02/18/want-decades-of-passive-income-buy-this-etf-and/?source=iedfolrf0000001,"Want Decades of Passive Income? Buy This ETF and Hold It Forever. The article discusses the benefits of dividend-paying stocks and ETFs, highlighting the Schwab U.S. Dividend Equity ETF as a particularly compelling option due to its solid dividend yield, growing payouts, and low expense ratio."
2025-02-18 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/18/3028177/0/en/Hemophilia-Market-Insights-Key-Trends-and-Developments-Across-Different-Types-of-Hemophilia-DelveInsight.html,"Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight The hemophilia market is expected to grow significantly due to advancements in gene therapy, innovative treatments, and increasing focus on personalized medicine. Rising awareness, early diagnosis, and expanding healthcare infrastructure in emerging markets are further driving market demand."
2025-02-20 09:45:00+00:00,https://www.fool.com/investing/2025/02/20/the-smartest-dividend-stocks-to-buy-with-1000-righ/?source=iedfolrf0000001,"The Smartest Dividend Stocks to Buy With $1,000 Right Now The article discusses five dividend-paying stocks that could be attractive investments: Pfizer, Verizon Communications, Vici Properties, Medtronic, and United Parcel Service. It highlights the companies' dividend yields, growth prospects, and valuation metrics."
2025-02-20 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/20/3029945/0/en/Antibody-Drug-Conjugates-Market-to-Witness-Rapid-Growth-Across-7MM-During-the-Study-Period-2020-2034-as-New-Innovations-Drive-Therapy-Advancements-DelveInsight.html,"Antibody-Drug Conjugates Market to Witness Rapid Growth Across 7MM During the Study Period (2020–2034) as New Innovations Drive Therapy Advancements | DelveInsight The antibody-drug conjugates market is expected to grow significantly in the 7MM by 2034, driven by advances in targeted therapies and ongoing research to enhance the effectiveness and safety of these treatments."
2025-02-21 10:50:00+00:00,https://www.fool.com/investing/2025/02/21/2-no-brainer-healthcare-stocks-to-buy-with-500-rig/?source=iedfolrf0000001,"2 No-Brainer Healthcare Stocks to Buy With $500 Right Now The article recommends two healthcare stocks, Vertex Pharmaceuticals and Pfizer, as good investment options with $500. Vertex is praised for its monopoly in cystic fibrosis treatments, growth opportunities, and promising pipeline, while Pfizer is seen as a value and income play despite facing patent cliffs."
2025-02-21 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/21/3030520/0/en/Hyperlipidemia-Drugs-Market-Size-to-Promote-USD-31-49-Bn-by-2034.html,"Hyperlipidemia Drugs Market Size to Promote USD 31.49 Bn by 2034 The global hyperlipidemia drugs market is expected to grow from $24.47 billion in 2025 to $31.49 billion by 2034, driven by factors like rising awareness, development of better drugs, and increasing cardiovascular diseases."
2025-02-21 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/21/3030613/0/en/Cell-and-Gene-Therapies-in-Rare-Disorders-Market-to-Skyrocket-Across-the-7MM-During-the-Forecast-Period-2025-2034-DelveInsight.html,"Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders."
2025-02-21 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/21/3030614/0/en/Evolving-Landscape-of-Obesity-Key-Market-Insights-of-Latest-Published-Different-Types-of-Obesity-DelveInsight.html,"Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight The obesity market is projected to grow from 2024 to 2034 due to the rising prevalence of obesity and the extensive pipeline of emerging drugs with improved safety profiles. The article discusses different types of obesity, including hypothalamic, pediatric, POMC deficiency, and syndromic/monogenic obesity, and the current treatment landscape and pipeline for each."
2025-02-23 09:53:00+00:00,https://www.fool.com/investing/2025/02/23/3-ultra-high-yield-dividend-stocks-you-can-buy-and/?source=iedfolrf0000001,"3 Ultra-High-Yield Dividend Stocks You Can Buy and Hold Forever The article discusses three high-dividend stocks that can be held for the long term: Ares Capital, Enterprise Products Partners, and Pfizer. These companies offer attractive dividend yields and are well-positioned to capitalize on their respective market opportunities."
2025-02-23 20:26:00+00:00,https://www.fool.com/investing/2025/02/23/prediction-these-could-be-the-best-performing-valu/?source=iedfolrf0000001,"Prediction: These Could Be the Best-Performing Value Stocks Through 2030 The article discusses two undervalued pharmaceutical stocks, Pfizer and Novo Nordisk, that could outperform the market due to their growth prospects and cheap valuations. Pfizer is benefiting from its oncology pipeline, while Novo Nordisk is a leader in the growing GLP-1 agonist market."
2025-02-24 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/24/3031261/0/en/Questex-s-Fierce-Pharma-Unveils-the-Conference-Program-for-the-Inaugural-Fierce-Pharma-Engage-Over-100-Speakers-Confirmed-to-Deliver-Unparalleled-Education.html,"Questex’s Fierce Pharma Unveils the Conference Program for the Inaugural Fierce Pharma Engage, Over 100 Speakers Confirmed to Deliver Unparalleled Education Questex's Fierce Pharma has unveiled the conference program for the inaugural Fierce Pharma Engage, an exclusive summit for pharma and biotech marketing, dealmaking, communications and medical affairs executives. The event will feature over 100 speakers from leading pharmaceutical and biotechnology companies."
2025-02-24 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/24/3031431/0/en/TALTZ-s-Rapid-Market-Ascent-Reflects-its-Unparalleled-Ability-to-Transform-the-Treatment-Landscape-for-Autoimmune-Diseases-DelveInsight.html,"TALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, and axial spondyloarthritis. With expanding indications and competitive efficacy, it continues to gain market share against rivals."
2025-02-24 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/24/3031432/0/en/CD47-Antigen-Inhibitors-Clinical-Trial-Pipeline-Insights-Featuring-20-Companies-DelveInsight.html,"CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight The rising global cancer incidence is driving the demand for novel CD47 inhibitor therapies. Recent clinical trials have shown promising results, particularly in hard-to-treat cancers like AML, boosting investor confidence. A strong pipeline of investigational drugs and increased R&D investments highlight the industry's commitment to advancing CD47-targeted immunotherapies."
2025-02-26 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/26/3033050/0/en/Derm-Biome-s-DB-007-5-is-highly-effective-at-treating-atopic-dermatitis-and-reducing-itch-in-preclinical-study-outperforming-the-current-leading-topical-AD-drug.html,"Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug Derm-Biome's topical drug DB-007-5 was highly effective at treating atopic dermatitis and reducing itch in a preclinical study, outperforming the current leading topical AD drug Opzelura."
2025-02-28 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/28/3034964/0/en/OPZELURA-Continues-to-Revolutionize-Dermatology-Market-with-Strong-Market-Uptake-DelveInsight.html,"OPZELURA Continues to Revolutionize Dermatology Market with Strong Market Uptake | DelveInsight OPZELURA, a topical JAK inhibitor cream, has shown strong market growth driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Expanding reimbursement coverage and rising physician confidence contribute to its market penetration."
2025-03-01 10:51:00+00:00,https://www.fool.com/investing/2025/03/01/3-dividend-stocks-that-are-no-brainer-buys-right/?source=iedfolrf0000001,"3 Dividend Stocks That Are No-Brainer Buys Right Now Three Motley Fool contributors recommend Johnson & Johnson, Novartis, and Pfizer as no-brainer dividend stocks due to their strong balance sheets, diversified businesses, and ability to navigate regulatory changes."
2025-03-02 09:21:00+00:00,https://www.fool.com/investing/2025/03/02/2-top-stocks-beaten-down-near-52-week-lows-that-lo/?source=iedfolrf0000001,"2 Top Stocks Beaten Down Near 52-Week Lows That Look Like Bargains Now Pfizer and UnitedHealth Group have seen their stock prices decline, but both companies have strategies to offset challenges. Pfizer's pipeline and UnitedHealth's physician employment model suggest they could be good long-term investments."
2025-03-03 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/03/03/3035899/0/en/JAK-Inhibitors-Clinical-Trial-Pipeline-Appears-Robust-With-50-Key-Pharma-Companies-Actively-Working-in-the-Therapeutics-Segment-DelveInsight-DelveInsight.html,"JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight The article discusses the robust pipeline of JAK inhibitors, with over 50 key pharmaceutical companies actively working on developing new drugs in this therapeutic segment. The pipeline includes promising JAK inhibitors in various stages of clinical trials, targeting a range of autoimmune disorders and cancer."
2025-03-04 14:45:00+00:00,https://www.fool.com/investing/2025/03/04/1-stock-down-43-that-looks-too-cheap-to-ignore/?source=iedfolrf0000001,"1 Stock Down 43% That Looks Too Cheap to Ignore Pfizer, the pharmaceutical giant, has faced headwinds in recent years, including a decline in COVID-19-related sales. However, the company has a strong pipeline of new products, including vaccines and cancer treatments, and is focused on cost-cutting measures. Despite the challenges, Pfizer's shares appear attractively valued, making it a potential long-term investment opportunity for patient investors."
2025-03-04 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/03/04/3036869/0/en/BALVERSA-Adoption-on-the-Rise-Meeting-Unmet-Needs-in-Advanced-Urothelial-Cancer-DelveInsight.html,"BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight BALVERSA (erdafitinib), a targeted therapy for FGFR-altered urothelial carcinoma, has strong market potential as precision oncology gains emphasis. Its uptake is expected to increase, especially if expanded to earlier treatment lines or additional FGFR-driven tumors."
2025-03-08 13:30:00+00:00,https://www.fool.com/investing/2025/03/08/3-top-dividend-stocks-to-buy-in-march/?source=iedfolrf0000001,"3 Top Dividend Stocks to Buy in March The article discusses the benefits of investing in dividend stocks, highlighting three companies - Pfizer, Verizon, and Realty Income - that have a history of reliable and growing dividends. It provides an overview of each company's dividend track record, growth prospects, and financial performance."
2025-03-10 00:30:00+00:00,https://www.globenewswire.com/news-release/2025/03/10/3039425/0/en/Global-Prostate-Cancer-Market-to-Reach-USD-29-2-Billion-by-2035-Driven-by-Aging-Population-and-Awareness-Future-Market-Insights-Inc.html,"Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc. The global prostate cancer market is expected to grow from $12.9 billion in 2025 to $29.2 billion by 2035, driven by the increasing prevalence of prostate cancer and advancements in diagnostic tools and treatment options."
2025-03-10 12:42:30+00:00,https://www.fool.com/data-news/2025/03/10/biontech-surpasses-q4-revenue-estimates/?source=iedfolrf0000001,"BioNTech Surpasses Q4 Revenue Estimates BioNTech SE reported strong Q4 2024 earnings, with EPS exceeding expectations despite a decline in COVID-19 vaccine revenue. The company is focused on expanding its oncology pipeline and diversifying beyond pandemic-driven revenue."
2025-03-12 12:48:00+00:00,https://www.globenewswire.com/news-release/2025/03/12/3041385/28124/en/Bispecific-Antibody-Market-Opportunity-Drug-Dosage-Patent-Price-Sales-Clinical-Trials-Insight-2030-New-Report-Highlights-600-Bispecific-Antibodies-in-Clinical-Trials-Worldwide.html,"Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide The bispecific antibody market is experiencing rapid growth, projected to reach $50 billion by 2030. This is driven by increasing clinical trials, with over 600 candidates under development. Leading therapies like Hemlibra and Vabysmo (Roche) have already dominated 75% of sales, while emerging treatments like Linvoseltamab and Odronextamab are under FDA review."
2025-03-12 21:24:01+00:00,https://www.benzinga.com/general/biotech/25/03/44290984/gsk-and-pfizer-viiv-healthcares-mid-stage-study-shows-strong-hiv-viral-suppression-with-long-acti,"GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study GSK and Pfizer's ViiV Healthcare reported strong results from a study on their HIV treatment, with 96% of patients on the intravenous formulation and 88% on the subcutaneous formulation maintaining viral suppression at six months. The company also presented positive data on two other investigational HIV therapies."
2025-03-13 11:30:00+00:00,https://www.fool.com/investing/2025/03/13/this-could-be-the-catalyst-that-sends-summit-stock/?source=iedfolrf0000001,"This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year Summit Therapeutics' stock has been volatile, with its valuation reaching $13 billion despite the company not generating consistent revenue. The success of its cancer drug candidate, ivonescimab, will be crucial for the stock's future performance, as positive trial results could lead to a rally, while disappointing results could result in a significant sell-off."
2025-03-13 18:23:46+00:00,https://www.benzinga.com/general/biotech/25/03/44311862/pfizers-direct-to-consumer-model-faces-scrutiny-from-us-senators,"Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (UPDATED) U.S. senators have expressed concerns about Pfizer's telehealth platform PfizerForAll, which they believe may drive unnecessary prescriptions and higher costs for federal healthcare programs."
2025-03-15 08:38:00+00:00,https://www.fool.com/investing/2025/03/15/down-93-is-it-finally-time-to-buy-moderna/?source=iedfolrf0000001,"Down 93%, Is It Finally Time to Buy Moderna? Moderna's stock has plummeted from its 2021 peak, but its low valuation and robust pipeline make it an attractive acquisition target. However, concerns about the future of vaccine development in the U.S. may make it best to watch the stock from a distance for now."
2025-03-17 11:45:00+00:00,https://www.fool.com/investing/2025/03/17/5-reasons-the-schwab-us-dividend-equity-etf-is-a/?source=iedfolrf0000001,"5 Reasons the Schwab U.S. Dividend Equity ETF Is a Long-Term Buy for 2030 and Beyond The article recommends the Schwab U.S. Dividend Equity ETF (SCHD) as a long-term investment, citing its low fees, diversification, and potential for dividend income and growth."
2025-03-19 14:40:15+00:00,https://www.benzinga.com/general/health-care/25/03/44399226/pfizer-offloads-its-last-7-stake-in-consumer-health-haleon-for-over-3-billion,"Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion Pfizer has sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the second half."
2025-03-20 10:17:00+00:00,https://www.fool.com/investing/2025/03/20/1-reliable-dividend-stocks-you-can-buy-now-and-hol/?source=iedfolrf0000001,"1 Reliable Dividend Stock You Can Buy Now and Hold at Least a Decade Pfizer stock offers a high dividend yield of over 6% as the market faces uncertainty due to trade war fears. While Pfizer faces patent cliffs and declining COVID-19 product sales, its pipeline of new therapies and continued dividend growth potential make it an attractive investment option."
2025-03-20 13:45:00+00:00,https://www.fool.com/investing/2025/03/20/3-reasons-pfizer-stock-could-be-a-steal-of-a-deal/?source=iedfolrf0000001,"3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025 Pfizer's stock has been struggling, but its low valuation, high-yielding dividend, and potential for growth opportunities make it an attractive investment option. The company's financials are stable, and its revenue guidance for 2025 is comparable to its recent performance, suggesting its growth days are not over."
2025-03-21 16:31:09+00:00,https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed,"Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed UK pharmaceutical companies must pay 23.5%-35.6% of branded medicine sales revenue to the NHS, significantly higher than other European nations. This has led to a decline in the UK's share of global pharma R&D investment and medicine availability, prompting industry leaders to urge the government to address the excessive levies."
2025-03-22 10:44:00+00:00,https://www.fool.com/investing/2025/03/22/buying-these-dirt-cheap-stocks-could-be-a-brillian/?source=iedfolrf0000001,"Buying These Dirt-Cheap Stocks Could Be a Brilliant Move The article discusses three undervalued stocks that could be great investments: Altimmune, Moderna, and Pfizer. Altimmune is a high-risk, high-potential-reward play on its weight loss drug candidate. Moderna's stock has fallen significantly, but the company's mRNA platform and pipeline hold promise. Pfizer's low valuation and strong growth prospects make it an attractive option."
2025-03-27 10:45:00+00:00,https://www.fool.com/investing/2025/03/27/why-pfizer-is-my-largest-healthcare-position/?source=iedfolrf0000001,"Why Pfizer Is My Largest Healthcare Position Pfizer is a compelling investment opportunity due to its strong cash flow, diverse drug portfolio, and attractive 6.7% dividend yield, despite near-term challenges from declining COVID-19 product sales. The company's operational growth, cost-saving initiatives, and long-term patent protection provide a solid foundation for future performance."
2025-03-31 12:56:13+00:00,https://www.benzinga.com/general/biotech/25/03/44560777/vaxcyte-plans-to-drop-developing-one-pneumococcal-conjugate-vaccine,Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine Vaxcyte has selected the VAX-24 Mid-dose as the basis for advancing an optimized dose formulation to a potential Phase 3 program. The company plans to initiate an infant Phase 3 study with either VAX-24 or VAX-31 pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026.
2025-04-01 09:37:00+00:00,https://www.fool.com/investing/2025/04/01/where-will-eli-lilly-be-in-1-year/?source=iedfolrf0000001,"Where Will Eli Lilly Be in 1 Year? Eli Lilly is developing an oral GLP-1 agonist drug that could disrupt the market dominated by injectable GLP-1 agonists. The company's stock valuation is high, but the success of the oral drug could lead to significant growth in the coming years."
2025-04-01 09:50:00+00:00,https://www.fool.com/investing/2025/04/01/3-ultra-high-yield-dividend-stocks-to-buy-in-april/?source=iedfolrf0000001,"3 Ultra-High-Yield Dividend Stocks to Buy in April The article highlights three high-yield dividend stocks: Ares Capital, Energy Transfer, and Pfizer. Ares Capital offers an 8.68% dividend yield and has delivered strong returns. Energy Transfer has a 6.95% forward yield and plans to grow its distribution. Pfizer provides a 6.82% yield and is seen as a safe haven during market volatility."
2025-04-01 19:51:00+00:00,https://www.investing.com/analysis/3-value-stocks-worth-buying-in-current-market-conditions-200658956,"3 Value Stocks Worth Buying in Current Market Conditions The article discusses three value stocks that are worth buying in the current market conditions: Healthcare Realty Trust (HR), Pfizer (PFE), and Alphabet (GOOGL). The author believes these stocks are undervalued and present good long-term growth opportunities for investors."
2025-04-02 16:14:00+00:00,https://www.investing.com/analysis/3-stocks-leading-healthcares-comeback-as-wall-street-turns-defensive-200659000,"3 Stocks Leading Healthcare’s Comeback as Wall Street Turns Defensive As Wall Street turns defensive, three healthcare stocks are leading the sector's comeback: Gilead Sciences, Pfizer, and Hims & Hers Health. Gilead and Pfizer offer stability and growth potential, while Hims & Hers presents a riskier but promising growth opportunity."
2025-04-02 19:29:17+00:00,https://www.benzinga.com/general/biotech/25/04/44614171/uks-health-agency-endorses-pfizers-blood-cancer-combo-therapy-as-first-for-untreated-hodgkin-lymp,"UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients The UK's National Institute for Health and Care Excellence (NICE) has recommended Pfizer's Adcetris (brentuximab vedotin) in combination with other therapies for the treatment of previously untreated stage 3 or 4 CD30-positive Hodgkin lymphoma. This marks the first recommendation specifically for this patient population, and the treatment is expected to benefit around 800 patients annually."
2025-04-03 12:30:00+00:00,https://www.fool.com/investing/2025/04/03/better-beaten-down-stock-to-buy-pfizer-vs-moderna/?source=iedfolrf0000001,"Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna Pfizer and Moderna, two leading COVID-19 vaccine makers, have seen their revenue and earnings drop as the pandemic recedes. Pfizer's diversified portfolio and consistent dividend make it a more attractive option, while Moderna's pipeline holds more upside potential for growth-oriented investors."
2025-04-05 12:15:00+00:00,https://www.fool.com/investing/2025/04/05/4-dividend-stocks-to-double-up-on-right-now/?source=iedfolrf0000001,"4 Dividend Stocks to Double Up on Right Now The article discusses four dividend stocks - Pfizer, PepsiCo, Realty Income, and British American Tobacco - that have faced market pessimism but have resilient dividends and high yields, representing buying opportunities for long-term investors."
2025-04-08 08:52:00+00:00,https://www.globenewswire.com/news-release/2025/04/08/3057376/28124/en/Ophthalmology-Market-Report-2025-Industry-to-Reach-US-93-7-Billion-by-2030-Emerging-Research-Activities-of-Ophthalmology-Treatments-and-Availability-of-Grants-Present-Business-Oppo.html,"Ophthalmology Market Report 2025 | Industry to Reach US$93.7 Billion by 2030 | Emerging Research Activities of Ophthalmology Treatments and Availability of Grants Present Business Opportunities The global ophthalmology market is expected to grow at a CAGR of 6.62%, reaching $93.69 billion by 2030, driven by advancements in technology, personalized medicine, and improved healthcare access."
2025-04-09 09:32:00+00:00,https://www.fool.com/investing/2025/04/09/3-high-yielding-dividend-stocks-near-their-52-week/?source=iedfolrf0000001,"3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now The article recommends three dividend stocks - Pfizer, Lockheed Martin, and Rogers Communications - that are trading near their 52-week lows and could be good long-term investments due to their attractive dividend yields and stable fundamentals."
2025-04-10 09:59:00+00:00,https://www.globenewswire.com/news-release/2025/04/10/3059057/28124/en/Biopharmaceuticals-Global-Overview-Report-2025-Global-Market-to-Reach-698-7-Billion-by-2030-Fueled-by-Specialized-Therapies-Such-as-mAb-and-Gene-Treatments-a-Strong-Pipeline.html,"Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline The global biopharmaceuticals market is projected to grow to $698.7 billion by 2030, driven by the rising demand for specialized therapies like monoclonal antibodies and gene treatments, as well as advancements in technology and increased healthcare spending."
2025-04-10 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/04/10/3059600/0/en/Global-Prefilled-Syringes-Market-to-Cross-USD-28-Billion-by-2032-DelveInsight.html,"Global Prefilled Syringes Market to Cross USD 28 Billion by 2032 | DelveInsight The global prefilled syringes market is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection. The market is expected to reach USD 28 billion by 2032, with North America leading the growth."
2025-04-10 17:58:00+00:00,https://www.globenewswire.com/news-release/2025/04/10/3059632/0/en/Specialists-Set-Sights-on-CLE-Pipeline-as-Unmet-Needs-Persist-and-Candidate-Pool-Expands-According-to-Spherix-Global-Insights.html,"Specialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights The article discusses the evolving treatment landscape for cutaneous lupus erythematosus (CLE), with rheumatologists and dermatologists highlighting emerging therapies like Saphnelo, Sotyktu, and litifilimab as potential solutions to address unmet needs, particularly for patients with systemic involvement."
2025-04-11 07:06:00+00:00,https://www.fool.com/investing/2025/04/11/6-stocks-bought-during-wall-st-historic-volatility/?source=iedfolrf0000001,"6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility The author discusses 6 stocks he purchased during the recent market volatility, including Pfizer, Sirius XM, Intel, Fastly, BioMarin Pharmaceutical, and PubMatic, citing their apparent price dislocations and long-term potential."
2025-04-11 14:18:25+00:00,https://www.benzinga.com/markets/equities/25/04/44763172/why-this-chinese-biotech-could-be-pharmas-deepseek,"Why This Chinese Biotech Could Be Pharma's DeepSeek Akeso Inc., a Chinese biotech company, has seen its drug sales rise 25% last year to over 2 billion yuan, driven by the strong performance of its cancer immunotherapy drugs. The company's potential launch of ivonescimab in the U.S. next year could bring it significant new revenue in licensing milestone and sales-related payments."
2025-04-12 08:18:00+00:00,https://www.fool.com/investing/2025/04/12/1-deeply-undervalued-stock-buy-market-correction/?source=iedfolrf0000001,"1 Deeply Undervalued Stock to Buy in the Market Correction Pfizer's shares have been declining due to lower revenue from its coronavirus franchise, but the company's strong manufacturing capabilities in the U.S. and its deep pipeline of new products make it an attractive investment opportunity at current valuation levels."
2025-04-14 15:12:30+00:00,https://www.fool.com/investing/2025/04/14/eli-lilly-novo-nordisk-viking-therapeutics-all-pop/?source=iedfolrf0000001,"Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today Pfizer announced it will discontinue development of its oral GLP-1 weight loss pill danuglipron due to the risk of liver injury. This news benefits Eli Lilly, Novo Nordisk, and Viking Therapeutics, who are now in a better position in the GLP-1 weight loss drug market."
2025-04-14 21:33:00+00:00,https://www.globenewswire.com/news-release/2025/04/14/3061314/673/en/ROSEN-A-LEADING-INVESTOR-RIGHTS-LAW-FIRM-Encourages-Cerevel-Therapeutics-Holdings-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-CERE.html,"ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. (CERE) for allegedly making false and/or misleading statements in connection with its October 2023 secondary stock offering and January 2024 proxy statement. The lawsuit claims that the offering was orchestrated by Cerevel's controlling shareholders, Bain Capital and Pfizer, to allow Bain to increase its position at a discounted price before AbbVie's acquisition of Cerevel."
2025-04-15 11:39:00+00:00,https://www.fool.com/investing/2025/04/15/is-pfizer-still-a-buy-after-scrapping-its-weight-l/?source=iedfolrf0000001,"Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? Pfizer discontinued development of an experimental weight-management pill, highlighting the risks of drug development. The company also faces upcoming patent expirations for key products and a potential slowdown in FDA approvals due to staffing changes at the agency."
2025-04-15 22:53:08+00:00,https://www.fool.com/investing/2025/04/15/why-pfizer-stock-topped-the-market-on-tuesday/?source=iedfolrf0000001,"Why Pfizer Stock Topped the Market on Tuesday Pfizer halted the development of its investigational weight loss drug danuglipron after a patient suffered a liver injury during testing. However, investors remain optimistic as Pfizer has another weight loss treatment, PF-07976016, in its pipeline and is expected to pursue mergers, acquisitions, and licensing deals to build up its pipeline."
2025-04-17 19:31:10+00:00,https://www.benzinga.com/general/biotech/25/04/44876132/us-advisory-panel-votes-to-expand-recommendation-for-pfizer-gsks-rsv-vaccines-for-older-adults-be,"US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years The US Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes Pfizer's Abrysvo and GSK's Arexvy vaccines."
2025-04-18 08:26:00+00:00,https://www.globenewswire.com/news-release/2025/04/18/3063998/28124/en/Atopic-Dermatitis-Drugs-Market-Forecast-2025-2034-Rising-Drug-Approvals-and-Clinical-Trial-Successes-Propel-Revenue-Growth-Making-Atopic-Dermatitis-a-High-Growth-Market.html,"Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market The atopic dermatitis drugs market is projected to reach $31 billion by 2034, driven by the rising prevalence of the condition, advancements in biologic therapies, and growing awareness. The biologics segment led the market in 2024, with new biologic injections targeting inflammatory pathways expanding treatment options."
2025-04-18 08:28:00+00:00,https://www.globenewswire.com/news-release/2025/04/18/3064000/28124/en/Huntington-s-Disease-Treatment-Market-to-Hit-2-03-Billion-by-2033-Driven-by-Cutting-Edge-Therapies.html,"Huntington's Disease Treatment Market to Hit $2.03 Billion by 2033, Driven by Cutting-Edge Therapies The Huntington's Disease Treatment Market is forecasted to reach USD 2.03 billion by 2033, driven by rising disease prevalence, innovative therapies, and gene-based treatment breakthroughs. Key players like H Lundbeck and Pfizer are fueling research and development efforts worldwide."
2025-04-20 09:45:00+00:00,https://www.fool.com/investing/2025/04/20/3-ultra-high-yield-dividend-stocks-to-buy-right-no/?source=iedfolrf0000001,"3 Ultra-High-Yield Dividend Stocks to Buy Right Now That Are Dirt Cheap The article highlights three stocks with attractive dividend yields and valuations: Ares Capital, Enterprise Products Partners, and Pfizer. It discusses the potential benefits and risks of each stock for income investors."
2025-04-21 10:49:00+00:00,https://www.globenewswire.com/news-release/2025/04/21/3064531/28124/en/Gastric-Neuroendocrine-Tumors-Market-Report-2025-Advancements-in-Diagnostics-Propel-Early-Detection-of-gNETs.html,"Gastric Neuroendocrine Tumors Market Report 2025 | Advancements in Diagnostics Propel Early Detection of gNETs The gastric neuroendocrine tumor (gNET) market is projected to grow at a CAGR of 10.4% by 2032, driven by advancements in diagnostics and targeted therapies. Key challenges include high treatment costs and limited awareness, but emerging markets and R&D present growth opportunities."
2025-04-21 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/04/21/3064769/0/en/Meningococcal-Vaccines-Market-Size-to-Surpass-9-05-Billion-Globally-by-2032-at-10-4-CAGR-Coherent-Market-Insights.html,"Meningococcal Vaccines Market Size to Surpass $9.05 Billion, Globally, by 2032 at 10.4% CAGR: Coherent Market Insights The global meningococcal vaccines market is expected to grow significantly, driven by the rising burden of meningococcal disease and increasing government support for immunization programs. Key factors restraining growth include high vaccine costs and limited awareness in developing regions."
2025-04-21 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/04/21/3064768/0/en/Meperidine-Demerol-Market-Size-to-Reach-563-7-Million-Globally-by-2032-at-1-5-CAGR-Coherent-Market-Insights.html,"Meperidine (Demerol) Market Size to Reach $563.7 Million, Globally, by 2032 at 1.5% CAGR: Coherent Market Insights The global meperidine (Demerol) market is expected to grow from $507.9 million in 2025 to $563.7 million by 2032, driven by the increasing prevalence of chronic pain and surgical procedures. However, the market growth is limited by the side effects of meperidine and the shift towards safer alternatives."
2025-04-22 21:37:05+00:00,https://www.fool.com/investing/2025/04/22/why-vertex-pharmaceuticals-was-such-a-healthy-stoc/?source=iedfolrf0000001,Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday Vertex Pharmaceuticals (VRTX) stock rose nearly 3% on Tuesday after positive analyst coverage from UBS and Cantor Fitzgerald. The analysts cited increased demand for Vertex's next-generation pain relief treatment Journavx and the company's focus on high unmet medical needs.
2025-04-23 07:51:00+00:00,https://www.fool.com/investing/2025/04/23/sp-500-sell-off-2-ultra-high-yield-dividend-stocks/?source=iedfolrf0000001,"S&P 500 Sell-Off: 2 Ultra-High-Yield Dividend Stocks That Make for No-Brainer Buys The article highlights two ultra-high-yield dividend stocks, Ford Motor Company and Pfizer, that are attractive buys amid the recent market downturn. Ford's truck division and improving quality, along with Pfizer's diversified drug portfolio and attractive valuation, make them compelling long-term investments."
2025-04-23 09:07:00+00:00,https://www.fool.com/investing/2025/04/23/is-eli-lilly-stock-a-buy/?source=iedfolrf0000001,"Is Eli Lilly Stock a Buy? Eli Lilly's next-generation GLP-1 agonists, including orforglipron and retatrutide, are performing well in clinical trials, while competitors like Pfizer and Novo Nordisk have faced setbacks. This positions Eli Lilly to potentially increase its market share in the rapidly growing GLP-1 agonist market."
2025-04-23 10:40:00+00:00,https://www.fool.com/investing/2025/04/23/whats-next-for-pfizer-after-the-company-pulls-its/?source=iedfolrf0000001,"What's Next for Pfizer After the Company Pulls Its Weight Loss Drug? Pfizer has abandoned the development of its weight loss drug danuglipron due to potential liver issues in clinical trials. This setback leaves Pfizer with limited options in the lucrative GLP-1 obesity market, leading to speculation that the company may pursue an acquisition to bolster its pipeline."
2025-04-23 15:47:00+00:00,https://www.investing.com/analysis/eli-lilly-nails-oral-glp1-trialheres-what-it-means-for-lly-200659879,"Eli Lilly Nails Oral GLP-1 Trial — Here’s What It Means for the Stock Eli Lilly's experimental oral GLP-1 drug, orforglipron, showed impressive results in Phase 3 trials, outperforming the only approved oral GLP-1 medication. This could enable Lilly to capture a significant share of the oral GLP-1 market for type 2 diabetes and obesity treatments."
2025-04-24 08:51:00+00:00,https://www.fool.com/investing/2025/04/24/should-you-buy-the-3-highest-paying-dividend-stock/?source=iedfolrf0000001,"Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500? The article discusses whether investors should buy the three highest-paying dividend stocks in the S&P 500: Dow, LyondellBasell, and Pfizer. It analyzes the companies' high dividend yields, which are driven by their poor stock performance due to industry and economic challenges. The article suggests that while the stocks may deliver solid long-term returns, investors should not expect short-term gains."
2025-04-24 10:45:00+00:00,https://www.fool.com/investing/2025/04/24/2-no-brainer-stocks-to-buy-with-less-than-30/?source=iedfolrf0000001,"2 No-Brainer Stocks to Buy With Less Than $30 The article discusses two stocks trading under $30 per share that are worth investing in: Pfizer and Adyen. Pfizer's stock price has fallen, but the company has a deep pipeline and a strong dividend program. Adyen is a fintech company with a strong moat and growth potential."
2025-04-24 12:30:00+00:00,https://www.fool.com/investing/2025/04/24/5-all-weather-dividend-stocks-to-buy-right-now/?source=iedfolrf0000001,"5 All-Weather Dividend Stocks to Buy Right Now The article highlights five dividend-paying stocks that are well-positioned to weather market volatility and economic uncertainty. These companies offer a combination of current income, downside protection, and long-term growth potential."
2025-04-24 19:36:34+00:00,https://www.benzinga.com/25/04/44993778/guardant-health-collaborates-with-pfizer-to-support-development-and-commercialization-of-new-cancer-therapies-usi,"Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform Guardant Health and Pfizer have announced a strategic collaboration to use Guardant's liquid biopsy platform in Pfizer's oncology clinical trials, including monitoring circulating tumor DNA as a therapy response marker. The collaboration will also allow Pfizer to access Guardant's liquid biopsy tests in China."
2025-04-25 20:00:00+00:00,https://www.globenewswire.com/news-release/2025/04/25/3068605/9788/en/CERE-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Cerevel-Therapeutics-Holdings-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html,"CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. alleging violations of federal securities laws related to the acquisition of Cerevel by AbbVie Inc."
2025-04-26 13:50:00+00:00,https://www.globenewswire.com/news-release/2025/04/26/3068722/683/en/INVESTOR-ALERT-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Cerevel-Therapeutics.html,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics A class action lawsuit has been filed against Cerevel Therapeutics, Bain Capital, and Pfizer, alleging violations of federal securities laws related to Cerevel's secondary stock offering and acquisition by AbbVie."
2025-04-28 11:47:00+00:00,https://www.fool.com/investing/2025/04/28/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/?source=iedfolrf0000001,"3 Dividend Stocks to Buy and Hold for the Next Decade The article highlights three dividend stocks - Abbott Laboratories, AbbVie, and Pfizer - that are recommended as buy-and-hold investments for the next decade. The companies are praised for their stable dividends, growth potential, and reasonable valuations."
2025-04-28 20:00:00+00:00,https://www.globenewswire.com/news-release/2025/04/28/3069615/0/en/Nurix-Therapeutics-Presents-Data-at-the-AACR-2025-Annual-Meeting-Highlighting-the-Transformative-Potential-of-Its-Proprietary-DEL-AI-Platform-Leveraging-Machine-Learning-to-Speed-t.html,"Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs Nurix Therapeutics presented data at the AACR 2025 Annual Meeting showcasing the potential of its DEL-AI platform to accelerate the discovery of novel drugs by using machine learning to predict binders for a wide range of therapeutic targets, including previously 'undruggable' ones."
2025-04-29 15:31:50+00:00,https://www.benzinga.com/general/biotech/25/04/45073128/pfizers-covid-windfall-shrinks-expands-cost-cutting-efforts,"Pfizer's Covid Windfall Shrinks, Expands Cost-Cutting Efforts Pfizer's Q1 2025 earnings beat expectations, but sales declined 8% year-over-year due to a plunge in Paxlovid revenues. The company plans to save an additional $1.2 billion through cost-cutting efforts by 2027."
2025-04-30 07:15:00+00:00,https://www.fool.com/investing/2025/04/30/prediction-pfizers-loss-may-be-viking-therapeutics/?source=iedfolrf0000001,"Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain Pfizer's weight loss drug danuglipron faced setbacks, while Viking Therapeutics' VK2735 shows promise in clinical trials. This could benefit Viking as it delays a potential competitor and increases interest in its own weight loss treatment."
2025-04-30 08:51:00+00:00,https://www.fool.com/investing/2025/04/30/will-pfizer-will-acquire-altimmune-or-viking-thera/?source=iedfolrf0000001,"Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? Pfizer's experimental obesity drug danuglipron failed due to safety concerns, leading the company to consider acquiring Altimmune or Viking Therapeutics, which have promising obesity drug candidates. Pfizer may wait to see how its other obesity drug, PF-07976016, performs in clinical trials before making an acquisition decision."
2025-04-30 10:15:00+00:00,https://www.fool.com/investing/2025/04/30/pfizers-dividend-yield-is-75-is-it-still-safe/?source=iedfolrf0000001,"Pfizer's Dividend Yield Is 7.5%. Is It Still Safe? Pfizer's dividend yield is around 7.5%, raising concerns about its sustainability. The article analyzes Pfizer's payout ratio, free cash flow, and potential impact of tariffs to assess the safety of the dividend. It concludes that the dividend looks safe currently, and the stock's low valuation offers a good margin of safety for long-term investors."
2025-04-30 10:45:00+00:00,https://www.fool.com/investing/2025/04/30/this-high-yield-pharma-stock-looks-like-an-incredi/?source=iedfolrf0000001,"This High-Yield Pharma Stock Looks Like an Incredible Bargain Bristol Myers Squibb (BMY) offers a compelling combination of deep value and substantial income, trading at a nearly 60% discount to the S&P 500 with a 5.12% dividend yield. While facing challenges like patent cliffs and clinical setbacks, the company's strategic acquisitions and promising pipeline candidates create significant upside potential for patient investors."
2025-04-30 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/04/30/3071682/0/en/Metastatic-HR-HER2-Breast-Cancer-Market-The-Road-Ahead-for-Targeted-Therapies-and-Personalized-Medicine-DelveInsight.html,"Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight The metastatic HR+/HER2- breast cancer market is expected to grow due to the launch of several novel emerging therapies, which are anticipated to change the treatment landscape and improve survival outcomes for this patient population."
2025-05-01 17:17:00+00:00,https://www.investing.com/analysis/3-highyield-dividend-stocks-that-could-rally-near-52week-lows-200660230,"3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows The article discusses three high-yield dividend stocks trading near their 52-week lows but have catalysts for growth in 2025. The stocks are AES Corp, Pfizer Inc., and LyondellBasell Industries."
2025-05-02 07:51:00+00:00,https://www.fool.com/investing/2025/05/02/3-ultra-high-yield-dividend-stocks-to-buy-in-may/?source=iedfolrf0000001,"3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May Three high-yield dividend stocks, Pfizer, Verizon Communications, and PennantPark Floating Rate Capital, are highlighted as attractive investment opportunities due to their sustainable dividends and discounted valuations."
2025-05-02 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/02/3073343/0/en/Liver-Cancer-Treatment-Market-is-expected-to-generate-a-revenue-of-USD-8-88-Billion-by-2031-Globally-at-13-45-CAGR-Verified-Market-Research.html,"Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research® The global liver cancer treatment market is expected to grow at a CAGR of 13.45% from 2024 to 2031, driven by the rising incidence of liver cancer and the emergence of innovative therapies. However, high treatment costs and limited access to innovative therapies in developing regions pose challenges."
2025-05-02 20:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/02/3073511/9788/en/CERE-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Cerevel-Therapeutics-Holdings-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html,"CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. alleging violations of federal securities laws related to the acquisition of Cerevel by AbbVie Inc."
2025-05-06 08:33:31+00:00,https://www.fool.com/investing/2025/05/06/why-viking-therapeutics-stock-surged-nearly-20-hig/?source=iedfolrf0000001,"Why Viking Therapeutics Stock Surged Nearly 20% Higher in April Viking Therapeutics' leading drug candidate VK2735 is a promising weight-loss treatment, especially after Pfizer discontinued its competing drug danuglipron. VK2735 performed well in phase 2 trials and is set to enter phase 3 trials, raising hopes that it could become a blockbuster drug if approved."
2025-05-06 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/06/3075216/0/en/Pharmaceutical-CDMO-Market-Set-to-Surpass-315-08-Billion-by-2034-Driven-by-7-24-CAGR.html,"Pharmaceutical CDMO Market Set to Surpass $315.08 Billion by 2034, Driven by 7.24% CAGR The global pharmaceutical CDMO market is expected to grow from $156.62 billion in 2024 to $315.08 billion by 2034, driven by increasing R&D activities and demand for biologics. North America and Asia-Pacific are the dominant regions, with the U.S. and China leading the market."
2025-05-07 13:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/07/3076163/0/en/Giants-of-Cancer-Care-announces-the-13th-annual-class-of-inductees.html,"Giants of Cancer Care® announces the 13th annual class of inductees The 13th Annual Giants of Cancer Care Awards Ceremony will honor leading researchers and educators in oncology whose discoveries have advanced the field. The awards ceremony will take place on May 29, 2025, in Chicago."
2025-05-07 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/07/3076341/0/en/Generic-Oncology-Drugs-Market-Size-Estimated-to-Reach-USD-30-998-Mn-by-2034-Rising-Global-Cancer-Cases-Increase-Demand-for-Affordable-Treatments.html,"Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments The global generic oncology drugs market is expected to grow from $24.39 billion in 2025 to $30.99 billion by 2034, driven by rising cancer rates and demand for affordable treatments. The market is dominated by North America and is projected to see the fastest growth in Asia Pacific."
2025-05-11 12:29:00+00:00,https://www.globenewswire.com/news-release/2025/05/11/3078730/683/en/Faruqi-Faruqi-Reminds-Cerevel-Therapeutics-Investors-of-the-Pending-Class-Action-Lawsuit-with-a-Lead-Plaintiff-Deadline-of-June-3-2025-CERE.html,"Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - CERE A class action lawsuit has been filed against Cerevel Therapeutics, Bain Capital, and Pfizer on behalf of investors who sold Cerevel stock or were entitled to vote on the merger with AbbVie. The lawsuit alleges that the defendants made false and/or misleading statements and failed to disclose material facts related to Cerevel's secondary stock offering and the subsequent acquisition by AbbVie."
2025-05-13 08:46:00+00:00,https://www.globenewswire.com/news-release/2025/05/13/3079840/28124/en/Saudi-Arabia-Pharmaceutical-CDMO-Market-Research-Report-2025-Featuring-Tabuk-Manufacturing-Lifera-Saudi-Bio-Fresenius-Kabi-Hikma-Pharma-Pfizer-Novartis.html,"Saudi Arabia Pharmaceutical CDMO Market Research Report 2025 Featuring Tabuk Manufacturing, Lifera, Saudi Bio, Fresenius Kabi, Hikma Pharma, Pfizer, Novartis The Saudi Arabia Pharmaceutical CDMO market is projected to grow from $1.62 billion in 2024 to $2.24 billion by 2030, driven by rising domestic demand, health system modernization, and cost efficiency. Key players include Tabuk Manufacturing, Lifera, Saudi Bio, Fresenius Kabi, Hikma Pharma, Pfizer, and Novartis."
2025-05-13 08:59:00+00:00,https://www.globenewswire.com/news-release/2025/05/13/3079843/28124/en/Saudi-Arabia-Active-Pharmaceutical-Ingredients-Market-Forecasts-Opportunities-Report-2024-2025-2030-Featuring-Pfizer-Aurobindo-Pharma-Novartis-BASF-Viatris-and-Novo-Nordisk.html,"Saudi Arabia Active Pharmaceutical Ingredients Market Forecasts & Opportunities Report 2024-2025 & 2030 Featuring Pfizer, Aurobindo Pharma, Novartis, BASF, Viatris, and Novo Nordisk The Saudi Arabian active pharmaceutical ingredients (API) market is expected to grow significantly, driven by rising healthcare demand, government initiatives, and the shift towards generic medicines. However, the market faces challenges such as dependence on imported raw materials and regulatory complexities."
2025-05-14 22:05:00+00:00,https://www.fool.com/investing/2025/05/14/3-magnificent-sp-500-dividend-stocks-down-62-63-an/?source=iedfolrf0000001,"3 Magnificent S&P 500 Dividend Stocks Down 62%, 63%, and 64% to Buy and Hold Forever The article highlights three S&P 500 dividend stocks that have seen significant declines, making them attractive buys for long-term investors. The companies are Target, Pfizer, and PepsiCo."
2025-05-18 16:05:00+00:00,https://www.fool.com/investing/2025/05/18/dont-fall-for-these-3-dividend-stocks-they-may-hav/?source=iedfolrf0000001,"Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut. The article discusses three pharmaceutical companies - AbbVie, Medtronic, and Pfizer - and their shaky dividend outlooks due to factors like declining sales, high payout ratios, and rising debt levels. The article suggests investors should avoid these stocks for now."
2025-05-19 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/19/3083874/0/en/Iterum-Therapeutics-Announces-Extension-of-Term-of-Promissory-Note.html,"Iterum Therapeutics Announces Extension of Term of Promissory Note Iterum Therapeutics announced that Pfizer has agreed to extend the payment deadline for a $20 million regulatory milestone related to the approval of ORLYNVAH, Iterum's oral antibiotic. This extension will allow Iterum to strategically invest any near-term revenue from ORLYNVAH's sales into its successful launch."
2025-05-19 14:56:00+00:00,https://www.globenewswire.com/news-release/2025/05/19/3084176/28124/en/Bio-Pharmaceutical-Outsourcing-Report-March-2025-Edition-Trump-Tariffs-Drive-Pharma-Manufacturing-to-US-but-Risk-Inflation-and-Disruption.html,"Bio/Pharmaceutical Outsourcing Report, March 2025 Edition -  Trump Tariffs Drive Pharma Manufacturing to US but Risk Inflation and Disruption The report examines the impact of Trump tariffs on pharmaceutical manufacturing, with a shift towards US-based production but potential risks of inflation and supply chain disruption."
2025-05-20 10:59:00+00:00,https://www.globenewswire.com/news-release/2025/05/20/3084681/28124/en/Aplastic-Anemia-Global-Clinical-Trials-Review-2025-Explore-Trends-and-Enrollment-Data-in-Aplastic-Anemia-Clinical-Trials.html,"Aplastic Anemia Global Clinical Trials Review, 2025 | Explore Trends and Enrollment Data in Aplastic Anemia Clinical Trials The report provides an in-depth overview of the current clinical trials landscape for Aplastic Anemia, including analysis of trial numbers, enrollment, and prominent drugs undergoing trials."
2025-05-23 20:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/23/3087706/9788/en/CERE-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Cerevel-Therapeutics-Holdings-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html,"CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for alleged violations of federal securities laws related to the acquisition of Cerevel by AbbVie Inc."
2025-05-23 21:11:00+00:00,https://www.investing.com/analysis/pfizers-75-dividend-income-haven-or-house-of-cards-200661252,"Pfizer's 7.5% Dividend: Income Haven or House of Cards? Pfizer's high dividend yield of 7.5% raises concerns about its sustainability, as the company faces revenue challenges from patent expirations and the normalization of COVID-19 demand. While Pfizer's cash flow supports the dividend, its earnings payout ratio is high, and the company's growth strategy in oncology will be crucial to maintaining the dividend long-term."
2025-05-24 08:11:00+00:00,https://www.fool.com/investing/2025/05/24/us-pharmaceutical-imports-tariffs-stocks/?source=iedfolrf0000001,"U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result The U.S. government is considering imposing tariffs on imported pharmaceuticals, which could negatively impact several major drug companies that rely on overseas manufacturing, including Amgen, Pfizer, and AbbVie."
2025-05-25 08:10:00+00:00,https://www.fool.com/investing/2025/05/25/heres-what-history-says-dividend-kings/?source=iedfolrf0000001,"Investing for Passive Income? Here's What History Says About the Stability of Dividend King Stocks. Investing in Dividend King stocks, which have raised dividends for at least 50 consecutive years, can provide stable passive income and cushion portfolio performance during tough market times. History shows these stocks have delivered strong long-term returns, with dividends contributing significantly to overall gains."
2025-05-25 22:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/25/3087870/0/en/Madison-Realty-Capital-Originates-720-Million-Loan-for-Office-to-Residential-Conversion-of-Former-Pfizer-Headquarters.html,"Madison Realty Capital Originates $720 Million Loan for Office-to-Residential Conversion of Former Pfizer Headquarters Madison Realty Capital, a real estate private equity firm, has originated a $720 million loan to a joint venture between Metro Loft Developers and David Werner Real Estate Investments for the conversion of the former Pfizer headquarters in New York City into a 1,602-unit luxury rental apartment building."
2025-05-27 14:56:00+00:00,https://www.globenewswire.com/news-release/2025/05/27/3088804/28124/en/Schizophrenia-Drugs-Market-Research-Report-2025-2035-Advances-in-Antipsychotic-Drug-Development-Increasing-Prevalence-Greater-Awareness-and-Access-to-Mental-Health-Care-Bolster-Gro.html,"Schizophrenia Drugs Market Research Report 2025-2035: Advances in Antipsychotic Drug Development, Increasing Prevalence, & Greater Awareness and Access to Mental Health Care Bolster Growth The schizophrenia drugs market is experiencing significant changes, with the emergence of new treatments like ketamine-based therapies. North America is expected to continue leading the global market due to well-established healthcare infrastructure and increasing government funding for mental health initiatives."
2025-05-27 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/27/3088917/0/en/Liposarcoma-Clinical-Trial-Analysis-Key-Insights-into-Rich-Pipeline-Featuring-15-Companies-and-20-Therapies-DelveInsight.html,"Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. The pipeline features 15+ companies and 20+ therapies in various stages of development."
2025-05-28 08:15:00+00:00,https://www.fool.com/investing/2025/05/28/novo-nordisk-53-plunge-is-the-company-fumbling-it/?source=iedfolrf0000001,"Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? Novo Nordisk, the industry leader in the weight loss drug market, has seen its stock plummet 52% from its mid-2024 high. The market is worried about the company's ability to maintain its dominance as competition intensifies with the development of next-generation weight loss drugs. However, the article suggests that Novo Nordisk's current valuation may still be attractive, and the company deserves some more faith until proven otherwise."
2025-05-29 13:38:02+00:00,https://www.benzinga.com/markets/asia/25/05/45669646/pfizers-mega-deal-highlights-chinas-rising-role-in-global-pharma,"Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma Pfizer has agreed to a $1.25 billion deal with Chinese biotech company 3SBio for the rights to its experimental cancer drug, highlighting China's growing role in the global pharmaceutical industry."
2025-05-29 14:58:00+00:00,https://www.globenewswire.com/news-release/2025/05/29/3090536/28124/en/Penicillin-Market-Research-Report-2025-Global-12-5-Bn-Trends-Opportunities-and-Forecasts-2020-2030F.html,"Penicillin Market Research Report 2025 - Global $12.5+ Bn Trends, Opportunities, and Forecasts, 2020-2030F The penicillin market is expected to grow from $10.15 billion in 2024 to $12.58 billion by 2030, driven by the drug's efficacy and affordability in treating bacterial infections, particularly in developing regions. However, the market faces challenges from antibiotic resistance and competition from newer drugs."
2025-05-30 08:55:00+00:00,https://www.globenewswire.com/news-release/2025/05/30/3090909/28124/en/3-94-Bn-IV-Hydration-Therapy-Markets-Global-Industry-Size-Share-Trends-Opportunity-and-Forecast-2020-2030F.html,"$3.94 Bn IV Hydration Therapy Markets - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F The global IV hydration therapy market is expected to grow from $2.51 billion in 2024 to $3.94 billion by 2030, driven by the increasing incidence of chronic illnesses, rising surgical volumes, and the growing number of intravenous drug approvals. Technological advancements and personalized solutions are also boosting consumer demand for home-based, individualized care."
2025-05-30 08:56:00+00:00,https://www.globenewswire.com/news-release/2025/05/30/3090910/28124/en/The-World-Market-for-Smoking-Cessation-Nicotine-De-Addiction-Products-2025-2030-Precision-Counseling-Targeted-Pharmacogenomic-Therapies-and-Resilient-Supply-Chains-Present-Lucrativ.html,"The World Market for Smoking Cessation & Nicotine De-Addiction Products 2025-2030: Precision Counseling, Targeted Pharmacogenomic Therapies, and Resilient Supply Chains Present Lucrative Opportunities The global smoking cessation and nicotine de-addiction product market is expected to grow significantly from 2025 to 2030, driven by advancements in digital health, personalized medicine, and regulatory frameworks. Key players in the market include Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, and Teva Pharmaceutical Industries."
2025-06-01 08:14:00+00:00,https://www.fool.com/investing/2025/06/01/beat-sp-500-cash-gushing-dividend-stock-zts/?source=iedfolrf0000001,"Beat the S&P 500 With This Cash-Gushing Dividend Stock Zoetis, an animal healthcare company, has consistently delivered strong financial performance and is expected to continue growing its sales and earnings. The company's diverse portfolio of products, global footprint, and pricing power make it a compelling investment opportunity."
2025-06-01 13:15:00+00:00,https://www.fool.com/investing/2025/06/01/terrible-news-for-pfizer-stock-investors/?source=iedfolrf0000001,"Terrible News for Pfizer Stock Investors Pfizer's coronavirus portfolio, including its COVID-19 vaccine Comirnaty and therapy Paxlovid, has been critical to the company's financial results, accounting for about 17.5% of its top line in 2024. However, recent regulatory changes in the U.S. may make it more challenging for Pfizer to consistently generate solid revenue from Comirnaty, as the FDA has limited its recommendations for the vaccine. While this development won't have a significant impact on Pfizer's overall financial results, it adds to the company's existing headwinds."
2025-06-02 20:00:00+00:00,https://www.globenewswire.com/news-release/2025/06/02/3092311/9788/en/CERE-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Cerevel-Therapeutics-Holdings-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html,"CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. alleging violations of federal securities laws related to the acquisition of Cerevel by AbbVie Inc."
2025-06-03 07:06:00+00:00,https://www.fool.com/investing/2025/06/03/3-ultra-high-yield-dividend-stocks-no-brainer-buy/?source=iedfolrf0000001,"3 Safe Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 11.35% -- That Make for No-Brainer Buys in June The article highlights three high-yield dividend stocks that the author believes are compelling buys in June: Annaly Capital Management, Pfizer, and PennantPark Floating Rate Capital. The author cites favorable industry conditions, strong financials, and attractive valuations as reasons for the positive sentiment."
2025-06-05 05:15:00+00:00,https://www.globenewswire.com/news-release/2025/06/05/3094099/0/de/Starke-Verkaufszahlen-f%C3%BCr-Cresemba-Isavuconazol-in-der-Region-Asien-Pazifik-und-China-l%C3%B6sen-weitere-Meilensteinzahlung-an-Basilea-aus.html,"Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen weitere Meilensteinzahlung an Basilea aus Basilea Pharmaceutica's antifungal drug Cresemba has seen strong sales growth in the Asia-Pacific region and China, triggering a $2.5 million milestone payment from its partner Pfizer. The growth, particularly in China, highlights the drug's high clinical value for patients with life-threatening fungal infections."
2025-06-05 05:15:00+00:00,https://www.globenewswire.com/news-release/2025/06/05/3094099/0/en/Strong-Cresemba-isavuconazole-sales-performance-in-Asia-Pacific-and-China-triggers-further-milestone-payment-to-Basilea.html,Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea Basilea Pharmaceutica Ltd announced that strong sales of its antifungal drug Cresemba in the Asia Pacific region and China triggered a $2.5 million milestone payment from its partner Pfizer.
2025-06-05 07:06:00+00:00,https://www.fool.com/investing/2025/06/05/all-6-stocks-ive-bought-through-5-months-of-2025/?source=iedfolrf0000001,"Here Are All 6 Stocks I've Bought Through 5 Months of 2025 The article discusses the stocks that the author has bought during the first five months of 2025, including Pfizer, PubMatic, Sirius XM, Intel, BioMarin Pharmaceutical, and Fastly. The author believes these stocks are undervalued and have long-term growth potential."
2025-06-05 07:34:00+00:00,https://www.fool.com/investing/2025/06/05/better-dividend-stock-to-buy-now-pfizer-vs-prologi/?source=iedfolrf0000001,"Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis Pfizer offers a high dividend yield but slower growth, while Prologis has a lower yield but faster dividend growth. Investors near retirement may prefer Pfizer, but income-seeking investors may find Prologis the better option."
2025-06-06 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/06/06/3095000/0/en/Nurix-Therapeutics-to-Host-a-Webcast-Conference-Call-to-Discuss-Data-from-the-Ongoing-Phase-1-Clinical-Trial-of-Bexobrutideg-NX-5948-Being-Presented-at-the-30th-European-Hematology.html,Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) Nurix Therapeutics will host a webcast conference call to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress.
2025-06-06 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/06/06/3095004/0/en/Arvinas-Announces-Submission-of-New-Drug-Application-to-U-S-FDA-for-Vepdegestrant-for-Patients-with-ESR1-Mutated-ER-HER2-Advanced-or-Metastatic-Breast-Cancer.html,"Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer Arvinas has submitted a New Drug Application to the FDA for vepdegestrant, a potential treatment for patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. The submission is based on positive results from the VERITAC-2 Phase 3 clinical trial."
2025-06-09 08:56:00+00:00,https://www.globenewswire.com/news-release/2025/06/09/3095659/28124/en/Selective-Estrogen-Receptor-Modulators-Market-Research-2025-2030-Leading-Players-Shaping-the-Future-of-Selective-Estrogen-Receptor-Modulators-Industry.html,"Selective Estrogen Receptor Modulators Market Research 2025-2030: Leading Players Shaping the Future of Selective Estrogen Receptor Modulators Industry The selective estrogen receptor modulators (SERMs) market is transforming, driven by innovations in receptor specificity and molecular design, as well as regulatory shifts and tariff impacts. The report provides insights into the evolving landscape, highlighting growth opportunities, regional dynamics, and leading players driving innovation."
2025-06-10 08:53:00+00:00,https://www.globenewswire.com/news-release/2025/06/10/3096389/28124/en/Rheumatoid-Arthritis-Global-Market-Research-Report-2025-2035-TNF-Inhibitors-IL-6-Inhibitors-and-JAK-Inhibitors-at-the-Forefront-of-Developing-Biologic-Therapies.html,"Rheumatoid Arthritis Global Market Research Report 2025-2035: TNF Inhibitors, IL-6 Inhibitors, and JAK Inhibitors at the Forefront of Developing Biologic Therapies The global rheumatoid arthritis market is highly competitive, with major pharmaceutical companies leading the development of innovative biologic therapies such as TNF inhibitors, IL-6 inhibitors, and JAK inhibitors. However, challenges like high costs and accessibility hinder the market's growth."
2025-06-13 15:41:00+00:00,https://www.investing.com/analysis/biontechs-curevac-deal-signals-deep-pivot-toward-mrna-cancer-therapies-200662216,"BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies BioNTech has acquired CureVac in a $1.25 billion all-stock deal, marking a strategic pivot for BioNTech towards cancer immunotherapy development using mRNA technology. The transaction aims to strengthen BioNTech's research, development, and commercialization capabilities for mRNA-based cancer treatments."
2025-06-20 14:59:00+00:00,https://www.globenewswire.com/news-release/2025/06/20/3102823/28124/en/Flu-RNA-Vaccines-Market-Research-Report-2025-2034-Global-Industry-Growth-Competitive-Landscape-Opportunities-and-Challenges.html,"Flu RNA Vaccines Market Research Report 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges The global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific."
2025-06-27 08:22:00+00:00,https://www.fool.com/investing/2025/06/27/want-to-collect-2000-in-dividends-each-year-heres/?source=iedfolrf0000001,"Want to Collect $2,000 in Dividends Each Year? Here's How Much You Should Aim to Invest in the Stock Market Today. The article discusses three high-yield ETFs that can help investors generate $2,000 in annual dividends by investing between $39,200 and $50,000, focusing on diversification and stable dividend income strategies."
2025-06-28 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/06/28/3106911/0/en/Microservices-in-Healthcare-Market-Size-to-Hit-USD-1-905-26-Million-by-2032-Driven-by-Cloud-Adoption-and-Healthcare-Digitization-SNS-Insider.html,"Microservices in Healthcare Market Size to Hit USD 1,905.26 Million by 2032, Driven by Cloud Adoption and Healthcare Digitization – SNS Insider The microservices in healthcare market is projected to grow from USD 334.59 million in 2023 to USD 1,905.26 million by 2032, with a CAGR of 21.34%, driven by cloud adoption, digital health initiatives, and healthcare digitization."
2025-07-04 08:30:00+00:00,https://www.fool.com/investing/2025/07/04/why-i-think-viking-therapeutics-is-an-asymmetric-g/?source=iedfolrf0000001,"Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity Viking Therapeutics is developing VK2735, an oral GLP-1/GIP receptor agonist for obesity treatment with unprecedented tolerability. Early phase 2 results show 14.7% weight loss and a unique 13% discontinuation rate matching placebo, potentially revolutionizing obesity drug market."
2025-07-05 10:30:00+00:00,https://www.fool.com/investing/2025/07/05/the-best-dividend-stocks-id-buy-right-now/?source=iedfolrf0000001,"The Best Dividend Stocks I'd Buy Right Now The article explores promising dividend-paying stocks and ETFs, highlighting companies like Pfizer, Caterpillar, UPS, and Chevron as potential long-term investment options with attractive dividend yields."
2025-07-10 07:06:00+00:00,https://www.fool.com/investing/2025/07/10/no-1-ultra-high-yield-dividend-stock-on-robinhood/?source=iedfolrf0000001,"This Is the No. 1 Ultra-High-Yield Dividend Stock Held by Retail Investors on Robinhood -- and It's Not Even Close Ford Motor Company is the top ultra-high-yield dividend stock on Robinhood, driven by its consistent F-Series truck sales, strategic EV investment approach, and attractive valuation, despite facing potential economic and trade headwinds."
2025-07-10 08:00:00+00:00,https://www.globenewswire.com/news-release/2025/07/10/3113016/0/en/Rakovina-Therapeutics-Highlights-Strength-of-Scientific-Advisory-Board-Driving-Innovation-in-AI-Enabled-Oncology-Drug-Development.html,"Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development Rakovina Therapeutics showcases its Scientific Advisory Board, comprised of leading experts in oncology and AI-driven drug discovery, to advance next-generation cancer therapies using artificial intelligence platforms."
2025-07-11 08:19:00+00:00,https://www.globenewswire.com/news-release/2025/07/11/3113856/28124/en/Burns-Market-Analysis-and-Forecast-Report-2025-2035-Featuring-Pfizer-Perrigo-Kenvue-Brands-3M-Smith-Nephew-Molnlycke-Cardinal-Health-Convatec-Haleon-Coloplast-DeRoyal-Industries.html,"Burns Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Perrigo, Kenvue Brands, 3M, Smith+Nephew, Molnlycke, Cardinal Health, Convatec, Haleon, Coloplast, DeRoyal Industries The global burns market is experiencing significant growth driven by increasing burn incidents, advanced wound care technologies, and innovations in regenerative medicine, with key players focusing on developing cost-effective treatment solutions."
2025-07-11 08:20:00+00:00,https://www.globenewswire.com/news-release/2025/07/11/3113857/28124/en/Burn-Pain-Market-Report-2025-2035-Focus-on-Treatment-Type-Burn-Type-and-Country-Analysis.html,"Burn Pain Market Report 2025-2035 | Focus on Treatment Type, Burn Type, and Country Analysis The global burn pain market is experiencing rapid expansion driven by increasing burn incidences, advancements in pain management technologies, and innovative therapies addressing complex burn pain challenges."
2025-07-11 08:21:00+00:00,https://www.globenewswire.com/news-release/2025/07/11/3113858/28124/en/Functional-Dyspepsia-Market-Analysis-and-Forecast-2025-2035-Competitive-Analysis-of-AstraZeneca-P-G-Takeda-Prestige-Consumer-Healthcare-Kenvue-Brands-Dr-Reddy-s-Pfizer-ZERIA-Daewoo.html,"Functional Dyspepsia Market Analysis and Forecast, 2025-2035, Competitive Analysis of AstraZeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong The functional dyspepsia market is experiencing growth through innovative pharmacological treatments, digital health solutions, and emerging therapies, with North America leading market development and significant potential in Asia-Pacific."
2025-07-14 08:47:00+00:00,https://www.globenewswire.com/news-release/2025/07/14/3114551/28124/en/Wet-Age-Related-Macular-Degeneration-Wet-AMD-Market-Analysis-Report-2025-2035-Long-Acting-Therapies-AI-Diagnostics-and-Personalized-Medicine-Set-to-Redefine-the-Future-Landscape.html,"Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape The global wet AMD market is expanding rapidly due to an aging population, technological advancements, and increased awareness. Anti-VEGF therapies dominate treatment, with emerging technologies like AI diagnostics and personalized medicine shaping future market potential."
2025-07-14 18:39:51+00:00,https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46401541/pfizer-faces-1-billion-ira-reform-hit-analysts-2025-outlook-flat,"Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook Pfizer anticipates a $1 billion net impact from Inflation Reduction Act reforms in 2025, with $1.5 billion in losses offset by $500 million in potential gains from Medicare Part D changes. Bank of America maintains a neutral rating with a $27 price target."
2025-07-16 08:12:00+00:00,https://www.fool.com/investing/2025/07/16/this-once-dominant-healthcare-stock-down-__-is-fin/?source=iedfolrf0000001,"This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback Pfizer experienced significant revenue decline after COVID-19 product demand dropped, but is now focusing on strategic cost savings, pipeline refinement, and oncology expansion to drive future growth."
2025-07-16 18:11:00+00:00,https://www.investing.com/analysis/4-highyield-largecaps-with-dividend-risk-and-opportunity-in-focus-200663805,"4 High-Yield Large-Caps With Dividend Risk and Opportunity in Focus The article analyzes four large-cap U.S. stocks offering high dividend yields, highlighting potential opportunities and risks for income-oriented investors across different sectors."
2025-07-19 08:27:00+00:00,https://www.fool.com/investing/2025/07/19/2-reliable-dividend-stocks-with-yields-above-6/?source=iedfolrf0000001,"2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now Two healthcare-related stocks, Healthpeak Properties and Pfizer, offer attractive dividend yields above 6% and potential for future dividend growth, despite challenges like patent cliffs and market changes."
2025-07-20 13:25:00+00:00,https://www.fool.com/investing/2025/07/20/should-you-forget-pfizer-and-buy-this-magnificent/?source=iedfolrf0000001,"Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? The article compares Pfizer and Merck as pharmaceutical dividend investments, highlighting Merck as potentially more attractive due to its consistent dividend history and lack of past dividend cuts during the Great Recession."
2025-07-21 12:15:00+00:00,https://www.fool.com/investing/2025/07/21/2-undervalued-healthcare-stocks-poised-to-dominate/?source=iedfolrf0000001,"2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade Two pharmaceutical giants, Pfizer and Novo Nordisk, are positioned for potential growth despite recent market underperformance. Pfizer is expanding its oncology pipeline, while Novo Nordisk continues to lead in diabetes and weight management medications."
2025-07-23 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/07/23/3120536/0/en/Global-Dysmenorrhea-Treatment-Market-to-Cross-USD-8-Billion-by-2032-DelveInsight.html,"Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight The dysmenorrhea treatment market is experiencing substantial growth driven by increased awareness, advanced diagnostics, and a growing demand for diverse treatment options including painkillers and hormonal therapies."
2025-07-29 05:15:00+00:00,https://www.globenewswire.com/news-release/2025/07/29/3122965/0/de/Basilea-initiiert-Phase-3-Studie-mit-Antipilzmittel-Fosmanogepix-bei-invasiven-Schimmelpilzinfektionen.html,"Basilea initiiert Phase-3-Studie mit Antipilzmittel Fosmanogepix bei invasiven Schimmelpilzinfektionen Basilea Pharmaceutica launched a Phase-3 clinical trial (FORWARD-IM) to evaluate the effectiveness and safety of Fosmanogepix, a broad-spectrum antifungal medication for treating invasive mold infections in adult patients. The study is expected to conclude in Q1 2028."
2025-07-29 05:15:00+00:00,https://www.globenewswire.com/news-release/2025/07/29/3122965/0/en/Basilea-initiates-phase-3-study-with-antifungal-fosmanogepix-in-invasive-mold-infections.html,"Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections Basilea Pharmaceutica launched a phase 3 clinical trial (FORWARD-IM) to evaluate fosmanogepix, a novel broad-spectrum antifungal drug for treating invasive mold infections in adult patients, with study completion expected in 2028."
2025-07-30 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/07/30/3124196/0/en/Drug-Discovery-Platforms-Market-Size-Expected-to-Reach-USD-635-45-Million-by-2034.html,"Drug Discovery Platforms Market Size Expected to Reach USD 635.45 Million by 2034 The global drug discovery platforms market is projected to grow from $186.24 million in 2024 to $635.45 million by 2034, driven by AI, technological advancements, and increased pharmaceutical R&D investments. North America leads the market, with Asia-Pacific expected to see the fastest growth."
2025-07-30 20:04:11+00:00,https://www.benzinga.com/markets/earnings/25/07/46737233/takeda-pharma-maintains-outlook-even-as-vyvanse-generics-hit-sales,"Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales Takeda Pharmaceutical reported a 30% year-over-year profit increase in Q1 2025, but experienced significant revenue decline from Vyvanse due to generic competition, causing stock price to drop."
2025-08-01 08:51:00+00:00,https://www.globenewswire.com/news-release/2025/08/01/3125640/28124/en/Testicular-Cancer-Market-Analysis-and-Forecast-Report-2025-2035-Emerging-Trends-Highlight-Shift-Towards-Immunotherapy-in-Testicular-Cancer.html,"Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Emerging Trends Highlight Shift Towards Immunotherapy in Testicular Cancer Global testicular cancer market is evolving with emerging trends in personalized therapies, immunotherapy, and fertility preservation, driven by key pharmaceutical companies focusing on innovative treatment approaches."
2025-08-01 09:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/01/3125643/28124/en/Fibromyalgia-Market-Analysis-Report-2025-2035-Key-Players-Drive-Competition-in-Expanding-Treatment-Options.html,"Fibromyalgia Market Analysis Report 2025-2035 | Key Players Drive Competition in Expanding Treatment Options Global fibromyalgia treatment market is expanding with novel drug developments, digital health tools, and personalized medicine approaches, driven by increasing awareness and technological innovations in pain management."
2025-08-01 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/01/3125742/0/en/Ascentage-Pharma-to-Participate-in-Evercore-China-Biotech-Summit.html,"Ascentage Pharma to Participate in Evercore China Biotech Summit Ascentage Pharma will participate in the Evercore China Biotech Summit in Shanghai, offering a fireside chat and investor meetings to discuss their innovative cancer drug pipeline and recent regulatory approvals."
2025-08-01 12:44:55+00:00,https://www.benzinga.com/markets/earnings/25/08/46791309/modernas-key-patent-win-overshadowed-by-gloomy-outlook,"Moderna's Key Patent Win Overshadowed By Gloomy Outlook Moderna reported Q2 earnings with a loss of $2.13 per share, beating estimates but experiencing a 41% revenue drop due to falling COVID-19 vaccine sales. The company received a key patent win against Pfizer/BioNTech but lowered its 2025 revenue outlook."
2025-08-02 08:23:00+00:00,https://www.fool.com/investing/2025/08/02/when-you-look-back-few-years-wish-bought-ai-stock/?source=iedfolrf0000001,"When You Look Back in a Few Years, You'll Wish You Had Bought This Unstoppable Artificial Intelligence (AI) Stock Microsoft reported strong quarterly results driven by AI products, with Copilot AI assistant experiencing rapid adoption and Azure cloud platform growing at its fastest pace in three years. The company became the second to reach a $4 trillion market capitalization, demonstrating significant potential in AI and cloud computing."
2025-08-04 11:15:00+00:00,https://www.fool.com/investing/2025/08/04/this-biotech-stock-could-soar-on-upcoming-clinical/?source=iedfolrf0000001,"This Biotech Stock Could Soar on Upcoming Clinical Data Viking Therapeutics is developing a dual-pathway GLP-1/GIP obesity drug with both injectable and oral delivery options, positioning itself as a potential disruptive force in the weight loss pharmaceutical market with an upcoming Phase 2 oral drug trial."
2025-08-04 14:32:30+00:00,https://www.benzinga.com/markets/earnings/25/08/46829145/biontech-narrows-losses-q2-revenue-doubles-as-vaccine-collaboration-drives-growth,"BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth BioNTech reported Q2 sales of $295.7 million, exceeding expectations, with a narrowed per-share loss. The company strengthened its oncology strategy through a collaboration with Bristol Myers Squibb and plans to acquire CureVac."
2025-08-05 00:05:00+00:00,https://www.fool.com/investing/2025/08/04/the-smartest-dividend-stocks-to-buy-with-10000-rig/?source=iedfolrf0000001,"The Smartest Dividend Stocks to Buy With $10,000 Right Now The article analyzes three dividend-paying stocks (UPS, Pfizer, and Lockheed Martin) that have experienced recent market challenges but potentially offer attractive investment opportunities due to strategic positioning and future growth potential."
2025-08-05 04:30:00+00:00,https://www.globenewswire.com/news-release/2025/08/05/3127014/0/en/Latest-Global-Paracetamol-Market-Size-Share-Worth-USD-1460-23-Million-by-2034-at-a-5-24-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-Segmentation-Gro.html,"[Latest] Global Paracetamol Market Size/Share Worth USD 1460.23 Million by 2034 at a 5.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) The global paracetamol market is projected to grow from USD 876.48 Million in 2024 to USD 1460.23 Million by 2034, with a steady 5.24% CAGR, driven by increasing healthcare awareness and rising incidences of chronic conditions."
2025-08-05 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/05/3127171/0/en/Iterum-Therapeutics-Reports-Second-Quarter-2025-Financial-Results.html,"Iterum Therapeutics Reports Second Quarter 2025 Financial Results Iterum Therapeutics plans to launch ORLYNVAH™, its first branded antibiotic for uncomplicated urinary tract infections, in August 2025. The company has partnered with EVERSANA for commercialization and has sufficient cash runway into 2026."
2025-08-05 14:01:00+00:00,https://www.investing.com/analysis/pfizer-q2-strong-execution-fx-tailwinds-and-guidance-upgrade-impress-200664849,"Pfizer Q2: Strong Execution, FX Tailwinds, and Guidance Upgrade Impress Pfizer reported strong Q2 2025 financial results, with revenues of $14.7 billion (10% increase) and adjusted EPS of $0.78, exceeding market expectations. The company raised its full-year adjusted EPS guidance and remains focused on cost savings and strategic growth initiatives."
2025-08-05 20:23:20+00:00,https://www.fool.com/data-news/2025/08/05/ideaya-idya-q2-net-loss-improves-27/?source=iedfolrf0000001,"IDEAYA (IDYA) Q2 Net Loss Improves 27% IDEAYA Biosciences reported a Q2 2025 net loss of $0.88 per share with no revenue, but maintained strong cash reserves of $991.9 million. The company continues advancing its cancer therapy pipeline, with key clinical trials progressing in darovasertib and other oncology programs."
2025-08-05 20:23:56+00:00,https://www.fool.com/investing/2025/08/05/why-shares-of-pfizer-soared-today/?source=iedfolrf0000001,"Why Shares of Pfizer Soared Today Pfizer reported better-than-expected Q2 earnings, raising its 2025 profit outlook. Despite stock performance challenges since the COVID-19 pandemic, the company remains optimistic about its future product pipeline."
2025-08-05 23:30:00+00:00,https://www.globenewswire.com/news-release/2025/08/05/3127982/0/en/Nxera-Launches-Broad-Proprietary-Pipeline-Targeting-Obesity-and-Chronic-Weight-Management.html,"Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management Nxera Pharma announces a new pipeline targeting obesity and metabolic disorders, featuring a proprietary oral small molecule GLP-1 agonist and six additional innovative programs focusing on GIP, Amylin, and Apelin receptors."
2025-08-06 02:22:22+00:00,https://www.fool.com/data-news/2025/08/06/itrm-reports-results/?source=iedfolrf0000001,"ITRM Reports Results Iterum Therapeutics reported a Q2 2025 loss of $0.13 per share, higher than expected, as the company prepares for the commercial launch of its oral antibiotic ORLYNVAH™ for urinary tract infections. The company has secured manufacturing agreements and extended its cash runway into 2026."
2025-08-06 11:15:00+00:00,https://www.fool.com/investing/2025/08/06/1-reason-to-buy-pfe-pfizer-stock/?source=iedfolrf0000001,1 Reason to Buy Pfizer (PFE) Stock Pfizer offers an attractive 7.4% dividend yield despite challenges from expiring drug patents and declining COVID-19 vaccine sales. The company has a solid drug development pipeline and appears undervalued based on current financial metrics.
2025-08-07 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/07/3129154/0/en/Ascentage-Pharma-to-Report-2025-Six-Month-Interim-Results-and-Provide-Corporate-Update-on-August-20-2025.html,"Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 Ascentage Pharma will release its 2025 six-month unaudited interim results and business updates on August 20, 2025, hosting investor webcasts in English and Chinese. The company is focused on developing innovative cancer therapies and has two approved products: Olverembatinib and Lisaftoclax."
2025-08-07 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/07/3129509/0/en/Cancer-Cachexia-Clinical-Trial-Pipeline-Shows-Potential-with-Active-Contributions-from-18-Key-Companies-DelveInsight.html,"Cancer Cachexia Clinical Trial Pipeline Shows Potential with Active Contributions from 18+ Key Companies | DelveInsight The cancer cachexia therapeutics market is gaining momentum with 18+ companies developing 20+ pipeline drugs to address weight loss, muscle wasting, and appetite loss in advanced cancer patients, driven by increased awareness and regulatory support."
2025-08-08 06:45:00+00:00,https://www.globenewswire.com/news-release/2025/08/08/3129935/0/en/Nxera-Pharma-Operational-Highlights-and-Consolidated-Results-for-the-Second-Quarter-and-First-Half-2025.html,"Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 Nxera Pharma reported increased revenues from PIVLAZ® and QUVIVIQ® in Japan, progress in partnered programs including Neurocrine's Phase 3 trial, and launched a new proprietary pipeline targeting obesity and weight management."
2025-08-10 10:05:00+00:00,https://www.fool.com/investing/2025/08/10/meet-yield-dividend-stock-could-soar-2026-pfe/?source=iedfolrf0000001,"Meet the 7.3% Yield Dividend Stock That Could Soar in 2026 Pfizer is experiencing post-pandemic challenges but shows promising growth in oncology and specialty drugs, with a high 7.3% dividend yield and potential for future stock appreciation."
2025-08-10 13:15:00+00:00,https://www.fool.com/investing/2025/08/10/2-beaten-down-stocks-to-buy-and-hold/?source=iedfolrf0000001,"2 Beaten-Down Stocks to Buy and Hold The article analyzes two stocks, Pfizer and Target, which have experienced recent challenges but potentially offer good long-term investment opportunities due to strategic transitions and consistent dividend payments."
2025-08-11 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/11/3130783/0/en/Ligand-Announces-Proposed-Offering-of-400-Million-of-Convertible-Senior-Notes-Due-2030.html,"Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 Ligand Pharmaceuticals plans to offer $400 million in convertible senior notes due in 2030, with potential additional $60 million option, to be sold to qualified institutional buyers. The company intends to use proceeds for general corporate purposes, potential investments, and share repurchases."
2025-08-12 00:15:00+00:00,https://www.fool.com/investing/2025/08/11/pfizer-just-beat-its-earning-estimates-is-this-the/?source=iedfolrf0000001,"Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock? Pfizer reported strong Q2 earnings with 10% revenue growth and increased sales in coronavirus vaccines, RSV vaccines, and key drug products. Despite challenges with patent expirations, the company shows potential through cost reduction, oncology pipeline, and new product approvals."
2025-08-12 01:16:00+00:00,https://www.fool.com/investing/2025/08/11/if-youd-invested-1000-in-pfe-3-years-ago-pfizer/?source=iedfolrf0000001,"If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today An investment of $1,000 in Pfizer three years ago would now be worth $585, underperforming the S&P 500. However, the company shows promise through its robust drug pipeline, ongoing approvals, cost-cutting efforts, and attractive 7% dividend yield."
2025-08-12 03:46:00+00:00,https://www.globenewswire.com/news-release/2025/08/12/3131390/0/en/Ligand-Announces-Pricing-of-400-Million-Convertible-Senior-Notes-Offering.html,"Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering Ligand Pharmaceuticals plans to issue $400 million in convertible senior notes due in 2030, with an option to increase the offering by $60 million. The notes will have a 0.75% interest rate and can be converted into common stock under certain conditions."
2025-08-12 14:46:59+00:00,https://www.benzinga.com/news/health-care/25/08/47062562/merck-pfizer-backed-therapy-improves-outcomes-for-cisplatin-ineligible-bladder-cancer-patients,"Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients Merck, in collaboration with Pfizer and Astellas Pharma, announced successful Phase 3 trial results for Keytruda-Padcev combination therapy in muscle-invasive bladder cancer patients, showing significant improvements in survival outcomes."
2025-08-12 17:41:06+00:00,https://www.benzinga.com/news/health-care/25/08/47069191/cdc-shooting-linked-to-suspects-covid-19-vaccine-beliefs-former-staff-blame-rfk-jr-hostility-tow,"CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency A gunman attacked CDC headquarters in Atlanta, allegedly motivated by anti-vaccine beliefs. Former CDC employees blame Robert F. Kennedy Jr.'s hostile rhetoric, and the NIH chief suggests mRNA vaccine platforms are losing public trust."
2025-08-13 02:30:00+00:00,https://www.globenewswire.com/news-release/2025/08/13/3132265/0/en/Latest-US-Personalized-Medicine-Market-Size-Share-Worth-USD-252-93-Billion-by-2034-at-a-17-32-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-Segmentati.html,"[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) The US personalized medicine market is projected to grow from $56.37 billion in 2024 to $252.93 billion by 2034, driven by genomic advancements, technological innovations, and increasing chronic disease prevalence."
2025-08-14 20:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/14/3133814/0/en/Ligand-Announces-Closing-of-Convertible-Senior-Notes-Offering.html,"Ligand Announces Closing of Convertible Senior Notes Offering Ligand Pharmaceuticals completed a $460 million convertible senior notes offering due in 2030, using proceeds for general corporate purposes, stock repurchases, and hedge transactions to manage potential stock dilution."
2025-08-15 11:15:00+00:00,https://www.fool.com/investing/2025/08/15/after-a-strong-quarterly-result-is-it-finally-safe/?source=iedfolrf0000001,"After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again? Pfizer reported strong Q2 2025 earnings, beating analyst estimates with $14.7 billion revenue and $0.78 EPS, but faces challenges from potential government pharmaceutical pricing policies and ongoing stock market uncertainty."
2025-08-15 14:37:00+00:00,https://www.investing.com/analysis/3-longterm-dividend-buys-you-can-get-for-under-50-200665391,"3 Long-Term Dividend Buys You Can Get for Under $50 The article highlights three dividend stocks under $50 that offer potential long-term value: Pfizer, Verizon, and Kinder Morgan. Each stock provides attractive dividend yields and potential price appreciation, representing opportunities for patient investors seeking steady returns."
2025-08-16 13:07:00+00:00,https://www.fool.com/investing/2025/08/16/2-top-dividend-stocks-to-buy-on-the-dip/?source=iedfolrf0000001,"2 Top Dividend Stocks to Buy on the Dip Both Pfizer and Merck face challenges in their pharmaceutical businesses, including patent expirations and competitive pressures, but show potential for long-term recovery through innovative pipelines, cost-cutting measures, and attractive dividend yields."
2025-08-18 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/18/3135218/0/en/PD-L-1-Inhibitors-Market-Set-to-Surge-During-the-Forecast-Period-2025-2034-as-Immuno-Oncology-Therapies-Gain-Momentum-DelveInsight.html,"PD-(L)1 Inhibitors Market Set to Surge During the Forecast Period (2025–2034) as Immuno-Oncology Therapies Gain Momentum | DelveInsight PD-(L)1 inhibitors are projected to dominate future drug sales, revolutionizing cancer care across multiple tumor types with flexible treatment approaches and promising clinical outcomes."
2025-08-19 18:28:51+00:00,https://www.benzinga.com/markets/large-cap/25/08/47218146/new-obesity-drugs-may-see-premium-pricing-undermined-by-underwhelming-data,"New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data Eli Lilly and Novo Nordisk are preparing to launch oral obesity treatment pills in 2026, with pricing expected to match existing injectable drugs, despite some underwhelming clinical trial data showing modest weight loss results."
2025-08-19 20:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/19/3135989/0/en/Ligand-to-Participate-in-September-Investor-Conferences.html,"Ligand to Participate in September Investor Conferences Ligand Pharmaceuticals executives will participate in two upcoming investor conferences: Citi 20th Annual BioPharma Conference in Boston and H.C. Wainwright 27th Annual Global Investment Conference in New York, presenting and hosting investor meetings."
2025-08-20 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/20/3136519/0/en/Questex-s-Fierce-Pharma-Week-Announces-Star-Studded-Lineup-with-Jamie-Lynn-Sigler-James-Van-Der-Beek-Selma-Blair-Kelly-Killoran-Bensimon-and-John-Duffield-to-Provide-Powerful-Stori.html,"Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing Questex's Fierce Pharma Week will feature celebrities like Jamie-Lynn Sigler, James Van Der Beek, and Selma Blair sharing personal health stories, alongside pharmaceutical industry leaders discussing innovation and patient experiences."
2025-08-20 23:57:00+00:00,https://www.globenewswire.com/news-release/2025/08/20/3136791/0/en/Ascentage-Pharma-Reports-2025-Interim-Unaudited-Six-Months-Financial-Results-and-Business-Updates.html,"Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates Ascentage Pharma reported strong sales growth for Olverembatinib, received approval for Lisaftoclax in China, and completed a top-up placement raising $190.1 million in net proceeds. The company continues advancing nine registrational clinical trials across multiple cancer therapies."
2025-08-21 08:38:00+00:00,https://www.globenewswire.com/news-release/2025/08/21/3136929/28124/en/Understanding-the-Nanomedicine-Landscape-Key-Players-and-Emerging-Trends.html,"Understanding the Nanomedicine Landscape: Key Players and Emerging Trends Nanomedicine is an emerging field combining nanotechnology with therapeutic molecules to enable targeted drug delivery, imaging, and diagnostics, offering more precise disease treatment approaches."
2025-08-21 09:59:00+00:00,https://www.globenewswire.com/news-release/2025/08/21/3136966/28124/en/Cytotoxic-Drugs-HPAPI-Manufacturing-Market-Industry-Trends-and-Global-Forecasts-to-2035-Over-140-Players-Now-Active-in-HPAPI-Cytotoxic-Drug-Contract-Manufacturing.html,"Cytotoxic Drugs & HPAPI Manufacturing Market Industry Trends and Global Forecasts to 2035 | Over 140 Players Now Active in HPAPI & Cytotoxic Drug Contract Manufacturing The global cytotoxic drugs and HPAPI manufacturing market is projected to grow from $11.7 billion to $39.9 billion by 2035, with a CAGR of 11.6%. Over 140 players are active in contract manufacturing, with Europe leading the market and increasing demand for targeted therapies driving growth."
2025-08-21 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/21/3137382/0/en/Global-Thyroid-Gland-Disorder-Treatment-Market-to-Increase-at-a-Steady-Growth-Rate-of-3-by-2032-DelveInsight.html,"Global Thyroid Gland Disorder Treatment Market to Increase at a Steady Growth Rate of ~3% by 2032 | DelveInsight The global thyroid gland disorder treatment market is expected to grow steadily at 3% by 2032, driven by increasing disease incidence, improved diagnostics, and advancements in biologic therapies."
2025-08-26 10:15:00+00:00,https://www.fool.com/investing/2025/08/26/viking-therapeutics-whats-next/?source=iedfolrf0000001,"Viking Therapeutics: What's Next? Viking Therapeutics experienced a 40% stock drop after releasing Phase 2 results for its oral weight loss drug VK2735, which showed 12.2% weight loss at 13 weeks. Despite initial market panic, analysts suggest the setback is due to dosing issues rather than fundamental scientific problems."
2025-08-27 08:50:00+00:00,https://www.globenewswire.com/news-release/2025/08/27/3139790/28124/en/Chronic-Inducible-Urticaria-CIndU-Market-Research-Report-2025-2035-Competitive-Analysis-of-AstraZeneca-Celldex-Therapeutics-J-J-Merck-Novartis-Pfizer-Regeneron-Pharma-Sanofi-Sun-Ph.html,"Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma The global CIndU market is experiencing significant growth driven by advancements in diagnostic tools, biologic therapies, and increasing awareness of immune mechanisms, with emerging personalized medicine approaches promising improved patient outcomes."
2025-08-27 08:59:00+00:00,https://www.globenewswire.com/news-release/2025/08/27/3139796/28124/en/Dyslipidemia-Market-Research-Report-2025-2035-Competitive-Analysis-of-Amgen-Sanofi-Regeneron-Pfizer-Novartis-Viatris-AbbVie-AstraZeneca-Horizon-Therapeutics-Esperion-Therapeutic.html,"Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic Global dyslipidemia market analysis reveals growing demand for personalized lipid-lowering treatments, with statins dominating therapy and technological advancements improving diagnosis and management, despite challenges in medication compliance and high drug costs."
2025-08-27 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/27/3139978/28124/en/Binge-Eating-Disorders-Global-Market-Research-Report-2025-2035-Featuring-Eli-Lilly-Amneal-Takeda-Tryp-Therapeutics-Tonix-Sumitomo-VIVUS-Novartis-and-Pfize.html,"Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize Global binge eating disorders market is growing due to advances in diagnostics, digital health technologies, and personalized treatments, with North America leading market expansion despite challenges like social stigma and high therapy costs."
2025-08-27 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/27/3140138/0/en/Human-Growth-Hormone-Market-to-Hit-USD-18-25-Billion-by-2032-Driven-by-Expanding-Therapeutic-Applications-and-Biotech-Advances-SNS-Insider.html,"Human Growth Hormone Market to Hit USD 18.25 Billion by 2032, Driven by Expanding Therapeutic Applications and Biotech Advances – SNS Insider The global Human Growth Hormone market is projected to grow from USD 7.15 billion in 2024 to USD 18.25 billion by 2032, driven by expanding therapeutic applications, biotech advances, and increasing demand for advanced biologics in pediatric and adult treatments."
2025-08-27 16:50:00+00:00,https://www.globenewswire.com/news-release/2025/08/27/3140255/0/en/Pfizer-and-BioNTech-s-COMIRNATY-Receives-U-S-FDA-Approval-for-Adults-65-and-Older-and-Individuals-Ages-5-through-64-at-Increased-Risk-for-Severe-COVID-19.html,"Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 Pfizer and BioNTech received FDA approval for their 2025-2026 COVID-19 vaccine targeting the LP.8.1 SARS-CoV-2 sublineage, approved for adults 65+ and high-risk individuals ages 5-64, with immediate shipping planned across U.S. pharmacies and healthcare facilities."
2025-08-27 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/27/3140258/0/en/Global-Pharmaceuticals-Market-to-Register-Immense-Growth-at-a-CAGR-of-7-by-2032-DelveInsight.html,"Global Pharmaceuticals Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight The global pharmaceutical market is projected to grow from USD 1.4 billion in 2024 to USD 2.4 billion by 2032, driven by rising chronic disease prevalence, biotechnology advancements, and increasing healthcare expenditure. North America is expected to lead market growth."
2025-08-29 09:14:00+00:00,https://www.investing.com/analysis/healthcare-is-sickly-but-these-dividend-yields-up-to-7-may-still-have-a-pulse-200666114,"Healthcare Is Sickly but These Dividend Yields up to 7% May Still Have a Pulse Healthcare stocks have been stagnant since April, but offer attractive dividend yields ranging from 5.3% to 7.1%. The article highlights several healthcare REITs and pharmaceutical companies with high dividend potential despite market challenges."
2025-09-01 13:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/01/3142150/0/en/Epinephrine-Market-to-Size-to-Reach-USD-5-74-Billion-by-2032-as-Demand-for-Emergency-Allergy-Treatments-Surges-SNS-Insider.html,"Epinephrine Market to Size to Reach USD 5.74 Billion by 2032 as Demand for Emergency Allergy Treatments Surges – SNS Insider The global epinephrine market is projected to grow from $2.77 billion in 2024 to $5.74 billion by 2032, driven by increasing cases of severe allergic reactions, technological advancements in auto-injectors, and rising awareness of anaphylaxis risks."
2025-09-01 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/01/3142183/0/en/Acne-Medicine-Market-Size-Projected-to-Reach-USD-23-33-Billion-by-2034.html,"Acne Medicine Market Size Projected to Reach USD 23.33 Billion by 2034 The global acne medication market is expected to grow from USD 14.86 billion in 2025 to USD 23.33 billion by 2034, with a 5.14% CAGR. North America dominates the market, driven by high acne prevalence, innovative treatments, and strong pharmaceutical presence."
2025-09-02 07:21:00+00:00,https://www.fool.com/investing/2025/09/02/3-high-yield-dividend-stocks-you-can-buy-in-septem/?source=iedfolrf0000001,"3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever The article discusses three high-yield dividend stocks: Realty Income, Healthpeak Properties, and Pfizer, which offer dividend yields above 5% and potential for long-term investment despite current market challenges."
2025-09-02 13:37:00+00:00,https://www.investing.com/analysis/healthcare-valuations-near-multiyear-lows-suggest-riskreward-asymmetry-200666254,"Healthcare Valuations Near Multi-Year Lows Suggest Risk–Reward Asymmetry The healthcare sector is experiencing low valuations and potential for a quiet rebound, with improving technical indicators and significant institutional investment despite ongoing political and economic challenges."
2025-09-03 08:49:00+00:00,https://www.globenewswire.com/news-release/2025/09/03/3143365/28124/en/Stomach-Cancer-Treatment-Market-Review-2020-2024-and-Forecast-2025-2030-Novel-Therapies-Increasing-Demand-for-Affordable-Treatments-and-Favorable-Reimbursement-Scenario-Position-th.html,"Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - Novel Therapies, Increasing Demand for Affordable Treatments, and Favorable Reimbursement Scenario Position the Market for Strong Growth The global stomach cancer treatment market is projected to grow from $5.51 billion in 2024 to $12.64 billion by 2030, driven by novel therapies, increasing demand for affordable treatments, and a favorable reimbursement scenario. Immunotherapy is emerging as a standard care, with key challenges including late diagnosis in low-resource settings."
2025-09-03 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/03/3143952/0/en/PDE4B-Inhibitor-Market-Poised-for-Strong-Growth-by-2034-DelveInsight.html,"PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight The PDE4B inhibitors market is expected to surge significantly by 2034, with promising therapeutic potential across respiratory, dermatologic, and inflammatory diseases. Emerging therapies and clinical trials are driving market expansion, targeting conditions like COPD, asthma, and cognitive impairment associated with schizophrenia."
2025-09-04 13:05:38+00:00,https://www.fool.com/data-news/2025/09/04/salesforce-posts-10-revenue-gain-in-q2/?source=iedfolrf0000001,"Salesforce Posts 10% Revenue Gain in Q2 Salesforce reported Q2 FY2026 earnings with $10.2 billion revenue, a 10% year-over-year increase. The company saw strong AI and Data Cloud growth, with annual recurring revenue exceeding $1.2 billion, up 120% year-over-year. Operating margin expanded to 34.3% for the 10th consecutive quarter."
2025-09-04 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/04/3144753/0/en/Monoclonal-Antibodies-Therapeutics-Market-Size-Projected-to-Reach-USD-1-057-91-Billion-by-2034.html,"Monoclonal Antibodies Therapeutics Market Size Projected to Reach USD 1,057.91 Billion by 2034 The global monoclonal antibody therapeutics market is expected to expand from $265.17 billion in 2024 to $1.06 trillion by 2034, with a 14.84% CAGR. North America currently dominates the market, while Asia Pacific is anticipated to experience the fastest growth, driven by increasing chronic disease cases and advancements in biotechnology."
2025-09-04 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/04/3144761/28124/en/Australia-Acute-Respiratory-Distress-Syndrome-Market-Growth-and-Company-Report-2025-2033-Featuring-Silence-Therapeutics-Gilead-Sciences-Terumo-Getinge-Livanova-Medtronic-Fresenius-.html,"Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer The Australia ARDS market is projected to grow from USD 24.82 million in 2024 to USD 44.79 million by 2033, driven by rising respiratory diseases, technological innovations, and post-COVID lung damage awareness."
2025-09-05 08:10:00+00:00,https://www.fool.com/investing/2025/09/05/down-34-should-you-buy-the-dip-on-viking-therapeut/?source=iedfolrf0000001,"Down 34%, Should You Buy the Dip on Viking Therapeutics? Viking Therapeutics is developing a weight loss drug candidate targeting the rapidly growing GLP-1 and dual GIP/GLP-1 receptor agonist market, currently dominated by Eli Lilly and Novo Nordisk. Despite mixed trial results, the company shows potential for future growth in the $95 billion projected weight loss drug market by 2030."
2025-09-07 13:30:00+00:00,https://www.fool.com/investing/2025/09/07/is-pfizer-a-millionaire-maker/?source=iedfolrf0000001,"Is Pfizer a Millionaire Maker? Pfizer's stock has dropped nearly 60% from its 2022 peak due to post-pandemic market corrections, but may present a long-term investment opportunity with a high dividend yield and potential for recovery."
2025-09-07 15:14:00+00:00,https://www.fool.com/investing/2025/09/07/think-its-too-late-buy-this-leading-biotech-stock/?source=iedfolrf0000001,"Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time. Viking Therapeutics' recent phase 2 trial of oral anti-obesity drug VK2735 disappointed investors due to high discontinuation rates, but the company may still attract pharmaceutical partners interested in its potential."
2025-09-08 18:13:05+00:00,https://www.benzinga.com/markets/large-cap/25/09/47555185/pfizer-biontech-roll-out-covid-19-update-that-boosts-antibodies-4-fold-in-high-risk-adults,"Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults Pfizer and BioNTech reported positive Phase 3 results for their 2025-2026 COVID-19 vaccine formula, showing a 4-fold increase in neutralizing antibodies in high-risk adults with no new safety issues."
2025-09-09 10:05:00+00:00,https://www.fool.com/investing/2025/09/09/the-best-ultra-high-yield-dividend-stock-to-invest/?source=iedfolrf0000001,"The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now Alexandria Real Estate, a healthcare-focused REIT, offers a 6.2% dividend yield and provides stable rental income from research properties across the healthcare sector, despite recent occupancy challenges."
2025-09-09 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/09/3146861/0/en/HCW-Biologics-Reports-Positive-Results-from-Non-Human-Primate-Study-for-Its-Proprietary-Second-Generation-T-Cell-Engager-Program.html,"HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program HCW Biologics announced successful development of second-generation T-cell engagers targeting solid tumors, particularly pancreatic cancer and glioblastoma, with promising preclinical safety results in non-human primates and potential for treating multiple cancer types."
2025-09-10 17:21:09+00:00,https://www.benzinga.com/news/fda/25/09/47604090/fda-moves-to-publicize-data-on-pregnant-womens-covid-vaccine-side-effects,"FDA Moves To Publicize Data On Pregnant Women's Covid Vaccine Side Effects The FDA is seeking to lift privacy rules on COVID-19 vaccine data for pregnant women to reveal potential side effects, amid ongoing debates about vaccine safety and transparency led by health officials like FDA Commissioner Marty Makary."
2025-09-11 03:30:00+00:00,https://www.globenewswire.com/news-release/2025/09/11/3148306/0/en/Questex-s-Fierce-Pharma-Announces-the-2025-Fierce-Pharma-Marketing-Awards-Winners.html,"Questex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards Winners Questex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges."
2025-09-12 22:19:00+00:00,https://www.fool.com/investing/2025/09/12/why-biontech-stock-sank-by-more-than-7-today/?source=iedfolrf0000001,"Why BioNTech Stock Sank by More Than 7% Today The Washington Post reported that government officials may link 25 children's deaths to coronavirus vaccines, causing BioNTech's stock to decline by 7% amid potential negative findings to be presented to a CDC advisory panel."
2025-09-15 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/15/3150285/0/en/Immune-Thrombocytopenic-Purpura-Market-to-Grow-at-a-Paltry-CAGR-of-1-9-During-the-Forecast-Period-2025-2034-DelveInsight.html,"Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight The immune thrombocytopenic purpura (ITP) market is expected to grow at a 1.9% CAGR from 2025-2034, with Sanofi's WAYRILZ approval marking a significant shift in treatment options and sparking competition among pharmaceutical companies developing novel therapies."
2025-09-16 08:22:00+00:00,https://www.fool.com/investing/2025/09/16/magnificent-sp-500-dividend-stocks-down-buy-hold/?source=iedfolrf0000001,"3 Magnificent S&P 500 Dividend Stocks Down as Much as 60% to Buy and Hold Forever The article discusses three S&P 500 dividend stocks trading at a discount: Pfizer, Accenture, and Occidental Petroleum, highlighting their potential for long-term investment and income generation."
2025-09-16 14:49:52+00:00,https://www.benzinga.com/news/health-care/25/09/47693785/moderna-reports-8-fold-jump-in-antibodies-with-updated-spikevax,"Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax Moderna released preliminary data on its 2025-2026 COVID-19 vaccine formula, showing an 8-fold increase in neutralizing antibodies against the LP.8.1 variant for high-risk adults and seniors, with no new safety concerns identified."
2025-09-18 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/18/3152708/0/en/Global-Overactive-Bladder-Treatment-Market-to-Exhibit-Substantial-Growth-at-a-CAGR-of-4-by-2032-DelveInsight.html,"Global Overactive Bladder Treatment Market to Exhibit Substantial Growth at a CAGR of ~4% by 2032 | DelveInsight The global overactive bladder treatment market is projected to grow from $3.8 billion in 2024 to $5.1 billion by 2032, with a CAGR of ~4%. North America leads market growth, driven by increasing OAB prevalence, aging population, and technological advancements in treatment therapies."
2025-09-19 10:46:00+00:00,https://www.globenewswire.com/news-release/2025/09/19/3153067/28124/en/South-Africa-Pharmaceutical-Market-Report-2025-with-Profiles-of-92-Companies-Such-As-Adcock-Ingram-Aspen-Cipla-Medpro-Novartis-Pfizer-GlaxoSmithKline-Dis-Chem-New-Clicks-and-More.html,"South Africa Pharmaceutical Market Report 2025, with Profiles of 92 Companies Such As Adcock Ingram, Aspen, Cipla Medpro, Novartis, Pfizer, GlaxoSmithKline, Dis-Chem, New Clicks, and More A comprehensive report on South Africa's pharmaceutical industry highlights market growth, challenges, and opportunities, focusing on local manufacturing, healthcare innovation, and emerging market trends."
2025-09-19 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/19/3153231/0/en/Maternal-Mental-Health-Market-to-Worth-USD-126-33-Billion-Rising-at-28-47-CAGR-by-2034.html,"Maternal Mental Health Market to Worth USD 126.33 Billion Rising at 28.47% CAGR by 2034 The global maternal mental health market is projected to grow from $10.32 billion in 2024 to $126.33 billion by 2034, driven by increasing awareness of perinatal mental health issues, technological advancements, and reduced stigma around mental health conditions."
2025-09-22 11:14:25+00:00,https://www.benzinga.com/news/health-care/25/09/47784482/pfizer-reportedly-nears-metsera-acquisition-deal-pfe-stock-climbs-in-monday-pre-market,"Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market Pfizer is in final stages of acquiring Metsera for up to $7.3 billion, offering $47.50 per share with potential additional $22.50 based on performance targets. The deal would provide Pfizer with an experimental anti-obesity drug to compete in the growing weight-loss treatment market."
2025-09-22 13:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/22/3153942/0/en/Global-Pharmerging-Market-2025-2030-Growth-at-9-66-CAGR-Says-Mordor-Intelligence-Report.html,"Global Pharmerging Market 2025-2030 Growth at 9.66% CAGR, Says Mordor Intelligence Report The global pharmerging market is projected to grow from USD 2.18 trillion in 2025 to USD 3.45 trillion by 2030, driven by increasing healthcare investments, OTC drug adoption, and expanding pharmaceutical infrastructure in emerging economies."
2025-09-22 13:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/22/3153941/0/en/Ectopic-Pregnancy-Market-Set-to-Surge-USD-16-09-Billion-by-2034-Driven-by-Rising-Awareness-and-Early-Detection.html,"Ectopic Pregnancy Market Set to Surge USD 16.09 Billion by 2034, Driven by Rising Awareness and Early Detection The global ectopic pregnancy market is projected to expand from USD 9.57 billion in 2025 to USD 16.09 billion by 2034, driven by rising awareness, early detection, and increased incidence of gynecological disorders."
2025-09-22 13:09:33+00:00,https://www.benzinga.com/m-a/25/09/47787042/pfizer-tries-to-revitalize-obesity-portfolio-with-5-billion-matsera-deal,"Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal Pfizer agreed to acquire Metsera for $47.50 per share, totaling approximately $4.9 billion, to expand its obesity and cardiometabolic disease drug portfolio. The deal includes potential milestone payments and is expected to close in Q4 2025."
2025-09-22 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/22/3154043/28124/en/Clostridioides-Difficile-Infections-CDI-Market-Insights-Report-2025-Robust-Pipeline-of-48-Molecules-Especially-Those-in-Phase-III.html,"Clostridioides Difficile Infections (CDI) Market Insights Report 2025: Robust Pipeline of 48 Molecules, Especially Those in Phase III A market research report reveals a robust CDI therapeutics pipeline with 48 molecules, including five in Phase III, highlighting significant market opportunities and strategic partnership potential in North America and Europe."
2025-09-22 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/22/3154090/0/en/Non-alcoholic-Steatohepatitis-Treatment-Market-Booms-at-28-14-CAGR-by-2034.html,"Non-alcoholic Steatohepatitis Treatment Market Booms at 28.14% CAGR by 2034 The global non-alcoholic steatohepatitis (NASH) treatment market is projected to grow from $7.75 billion in 2024 to $92.5 billion by 2034, driven by increasing obesity, diabetes, and metabolic disorders, with significant market expansion expected in North America and Asia-Pacific regions."
2025-09-22 18:14:00+00:00,https://www.investing.com/analysis/metsera-buyout-confirms-obesity-as-strategic-pivot-for-pfizers-growth-story-200667298,"Metsera Buyout Confirms Obesity as Strategic Pivot for Pfizer’s Growth Story Pfizer announced a $4.9 billion acquisition of Metsera, a biotechnology company with promising obesity treatment therapies, marking a strategic entry into the rapidly growing obesity treatment market."
2025-09-24 16:48:00+00:00,https://www.globenewswire.com/news-release/2025/09/24/3155721/28124/en/Pneumococcal-Vaccine-Market-Opportunities-and-Strategies-to-2034-Pediatric-Segment-Holds-the-Major-Opportunity-in-Market-Expansion.html,"Pneumococcal Vaccine Market Opportunities and Strategies to 2034 - Pediatric Segment Holds the Major Opportunity in Market Expansion Global pneumococcal vaccine market projected to grow from $7.92 billion in 2024 to $12.41 billion by 2034, driven by increased healthcare investments and pediatric vaccination demand."
2025-09-25 10:09:00+00:00,https://www.investing.com/analysis/pfizer-tries-to-fatten-its-profits-with-weight-loss-drugs-200667486,"Pfizer Tries to Fatten Its Profits With Weight Loss Drugs Pfizer is seeking to enter the lucrative weight loss drug market by offering $7.3 billion to acquire Metsera, a company with clinical-stage obesity drug programs, as the company faces potential revenue challenges from upcoming patent expirations."
2025-09-26 04:08:24+00:00,https://www.benzinga.com/news/health-care/25/09/47882383/robert-f-kennedy-jr-faces-impeachment-push-from-haley-stevens-over-health-care-chaos-and-rising-,"Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough' Representative Haley Stevens announced plans to draft articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr., criticizing his healthcare policies and claiming he has caused 'health care chaos' and rising costs."
2025-09-27 12:15:00+00:00,https://www.fool.com/investing/2025/09/27/is-pfizer-stock-a-buy-after-5-billion-glp-1-bet/?source=iedfolrf0000001,"Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet? Pfizer is expanding its presence in the growing GLP-1 weight loss market by acquiring Metsera for $4.9 billion, aiming to develop innovative oral and less frequent dosing weight management medicines to compete with market leaders Eli Lilly and Novo Nordisk."
2025-09-28 17:28:00+00:00,https://www.fool.com/investing/2025/09/28/why-pfizers-post-covid-future-looks-brighter-than/?source=iedfolrf0000001,"Why Pfizer's Post-COVID Future Looks Brighter Than Ever Despite declining COVID-19 vaccine and treatment sales, Pfizer is positioning itself for future growth through strategic acquisitions like Seagen, with promising cancer therapies such as Padcev and Elrexfio, and potential new treatments in development."
2025-09-29 07:20:17+00:00,https://www.benzinga.com/etfs/sector-etfs/25/09/47909507/trumps-100-drug-tariff-will-hit-americans-economist-says-buyers-eat-the-cost-not-foreign-firms,"Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms Economist Justin Wolfers warns that proposed 100% tariffs on foreign pharmaceuticals will likely be passed onto American patients and insurers, particularly for patented brand-name drugs with inelastic demand."
2025-09-30 16:01:59+00:00,https://www.fool.com/investing/2025/09/30/why-pfizer-stock-just-popped/?source=iedfolrf0000001,Why Pfizer Stock Just Popped Pfizer is preparing to reduce drug prices for Medicaid patients following pressure from the Trump administration's executive order aimed at lowering drug costs for U.S. customers to match prices in other wealthy nations.
2025-09-30 18:16:03+00:00,https://www.benzinga.com/news/health-care/25/09/47952073/pfizer-becomes-first-drugmaker-to-join-trumps-price-cut-push,"Pfizer Becomes First Drugmaker To Join Trump's Price Cut Push Pfizer agreed with the Trump Administration to lower prescription drug prices for U.S. patients, offering significant discounts on several medications and committing to invest $70 billion in U.S. research and development."
2025-09-30 18:33:00+00:00,https://www.investing.com/analysis/pfizer-underperformance-vs-sp-500-frames-context-for-trumpera-agreement-200667755,"Pfizer: Underperformance Vs. S&P 500 Frames Context for Trump-Era Agreement Pfizer agreed to a drug-pricing initiative with the Trump administration, offering medications through Medicaid at reduced prices linked to costs in wealthy nations, amid White House pressure to lower prescription drug prices for Americans."
2025-09-30 22:07:33+00:00,https://www.fool.com/data-news/2025/09/30/stock-market-today-pfizer-rallies-on-trump-drug-pr/?source=iedfolrf0000001,"Stock Market Today: Pfizer Rallies on Trump Drug Pricing Deal and U.S. Investment Pledge Pfizer surged after striking a landmark agreement with the Trump administration to lower drug prices and expand U.S. production, securing a three-year tariff exemption and committing to $70 billion in U.S. manufacturing investments."
2025-10-01 09:10:00+00:00,https://www.fool.com/investing/2025/10/01/got-200-2-healthcare-stocks-to-buy-hold-forever/?source=iedfolrf0000001,"Got $200? 2 Healthcare Stocks to Buy and Hold Forever The article explores two healthcare stocks with potential growth: Pfizer, a well-established pharmaceutical company, and CRISPR Therapeutics, an innovative gene-editing biotech firm. Both companies offer unique investment opportunities in the healthcare sector."
2025-10-01 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/01/3159365/0/en/Arvinas-to-Present-Clinical-Data-for-ARV-102-a-PROTAC-LRRK2-Degrader-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html,"Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders® Arvinas will present clinical data for ARV-102, an investigational oral PROTAC degrader targeting LRRK2, at the 2025 International Congress of Parkinson's Disease and Movement Disorders in Honolulu."
2025-10-01 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/01/3159828/0/en/Lyme-Disease-Market-Growth-Highlighted-by-Pipeline-Advances-and-Expanding-Patient-Population-DelveInsight.html,"Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight DelveInsight's analysis predicts growth in the Lyme disease market from 2025-2034, driven by emerging therapies and increased healthcare spending, with new vaccine and prevention technologies in development."
2025-10-01 17:27:40+00:00,https://www.fool.com/investing/2025/10/01/why-shares-in-novo-nordisk-bumped-higher-today/?source=iedfolrf0000001,"Why Shares in Novo Nordisk Bumped Higher Today Novo Nordisk's stock rose 6% following Pfizer's agreement with the Trump administration, which raised hopes for similar pharmaceutical manufacturing deals that could avoid potential 100% tariffs on imported drugs."
2025-10-01 21:08:42+00:00,https://www.fool.com/investing/2025/10/01/why-pfizer-stock-trounced-the-market-today/?source=iedfolrf0000001,Why Pfizer Stock Trounced the Market Today Pfizer's stock rose nearly 7% after announcing a deal with the government to lower prescription drug prices in the Medicaid program and commit to 'most favored nation' pricing for new U.S. drugs.
2025-10-01 22:13:33+00:00,https://www.fool.com/investing/2025/10/01/why-biontech-stock-jumped-by-nearly-4-on-wednesday/?source=iedfolrf0000001,"Why BioNTech Stock Jumped by Nearly 4% on Wednesday BioNTech showcased its AI subsidiary InstaDeep and its potential in developing individualized medicine, leading to a stock price increase of nearly 4%. The company's efforts in AI technology and positive news from partner Pfizer contributed to investor optimism."
2025-10-01 22:36:03+00:00,https://www.fool.com/investing/2025/10/01/why-abbvie-stock-cruised-to-an-almost-6-gain-today/?source=iedfolrf0000001,"Why AbbVie Stock Cruised to an Almost 6% Gain Today AbbVie announced a $70 million expansion of its Bioresearch Center in Worcester, Massachusetts, focusing on biologics research and manufacturing. The project aligns with the Trump administration's goal of increasing domestic corporate assets and is part of AbbVie's broader $10 billion biologics advancement strategy."
2025-10-02 08:18:00+00:00,https://www.investing.com/analysis/top-3-dividend-achievers-for-october-high-yields-growth-ahead-200667859,"Top 3 Dividend Achievers for October: High Yields, Growth Ahead The article highlights three dividend-achieving stocks with strong potential for growth and high dividend yields: United Parcel Service, Verizon, and Pfizer, each offering unique investment opportunities in Q4 2025."
2025-10-02 09:11:00+00:00,https://www.fool.com/investing/2025/10/02/3-mega-dividend-stocks-with-yields-as-high-as-134/?source=iedfolrf0000001,"3 Mega Dividend Stocks With Yields as High as 13.4% The article explores three high-dividend stocks: Annaly Capital Management, Western Midstream Partners, and Pfizer, each offering substantial dividend yields ranging from 6.3% to 13.4%, but with varying risk profiles and strategic challenges."
2025-10-02 11:02:00+00:00,https://www.fool.com/investing/2025/10/02/3-things-you-need-to-know-if-you-buy-pfizer-today/?source=iedfolrf0000001,"3 Things You Need to Know if You Buy Pfizer Today Pfizer offers an attractive 7.2% dividend yield but faces potential challenges including patent expirations for key drugs and a high dividend payout ratio, which could lead to future dividend cuts."
2025-10-02 16:15:00+00:00,https://www.investing.com/analysis/6-healthcare-stocks-positioned-to-soar-after-trumppfizer-deal-200667857,"6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal Pharmaceutical stocks rallied after Pfizer reached an agreement with the Trump administration to sell drugs at significant discounts, avoiding potential 100% tariffs. Multiple pharma companies saw substantial stock price increases."
2025-10-02 16:22:46+00:00,https://www.fool.com/investing/2025/10/02/astrazeneca-stock-is-up-10-on-tariff-news-but-is-t/?source=iedfolrf0000001,"AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy? AstraZeneca's stock rose over 10% this week, partly due to Pfizer's deal with the Trump administration that could potentially provide tariff exemptions and expansion opportunities for pharmaceutical companies."
2025-10-03 07:15:00+00:00,https://www.fool.com/investing/2025/10/03/pfizer-just-made-a-landmark-drug-pricing-agreement/?source=iedfolrf0000001,"Pfizer Just Made a Landmark Drug Pricing Agreement with President Donald Trump. Is the Stock a Buy? Pfizer struck a deal with President Trump to lower prices of primary care treatments by an average of 50%, gaining exemption from import tariffs and maintaining its earnings potential while addressing drug pricing concerns."
2025-10-03 08:20:00+00:00,https://www.fool.com/investing/2025/10/03/stocks-pay-6-dividend-yields-too-good/?source=iedfolrf0000001,"These 3 Stocks Pay More Than 6%. Are Their Dividend Yields Too Good to Be True? The article analyzes three high-yielding dividend stocks (Pfizer, Verizon, and Altria), examining their dividend sustainability, financial health, and potential risks for investors seeking income-generating investments."
2025-10-04 21:10:00+00:00,https://www.globenewswire.com/news-release/2025/10/04/3161304/0/en/ThinkCareBelieve-Week-37-America-Isn-t-Stopping.html,"ThinkCareBelieve: Week 37 America Isn’t Stopping President Trump signed an Executive Order on AI for childhood cancer research, launched TrumpRx for prescription drug pricing, addressed military leadership, and made progress on Middle East peace negotiations while maintaining strong economic performance."
2025-10-05 13:15:00+00:00,https://www.fool.com/investing/2025/10/05/can-pfizers-stock-break-this-disappointing-streak/?source=iedfolrf0000001,"Can Pfizer's Stock Break This Disappointing Streak? Pfizer is experiencing challenges with declining COVID vaccine sales and potential patent expirations, but recent government negotiations and strategic acquisitions offer potential for future growth. The stock has been struggling but shows signs of potential recovery."
2025-10-06 19:02:00+00:00,https://www.investing.com/analysis/from-defense-to-pharma-to-energy-dividend-opportunities-across-sectors-200668057,"From Defense to Pharma to Energy: Dividend Opportunities Across Sectors The article explores dividend opportunities in defense, pharmaceutical, and energy sectors, highlighting potential investment prospects in Lockheed Martin, Pfizer, and Schlumberger amid evolving market conditions and geopolitical dynamics."
2025-10-06 19:27:00+00:00,https://www.investing.com/analysis/q3-earnings-season-preview-little-suspense-200668058,"Q3 Earnings Season Preview: Little Suspense The Q3 earnings season is expected to show solid corporate performance, driven by AI investments, resilient economic growth, and potential low-teens earnings growth for the S&P 500, with the Magnificent Seven tech companies leading the way."
2025-10-07 07:15:00+00:00,https://www.fool.com/investing/2025/10/07/worried-about-tariffs-2-safe-haven-stocks-to-buy/?source=iedfolrf0000001,"Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500 Amid concerns about US import tariffs potentially impacting company earnings, Pfizer and Vertex Pharmaceuticals emerge as safe investment options due to their strategic positioning and manufacturing approaches."
2025-10-07 08:26:00+00:00,https://www.investing.com/analysis/eli-lilly-stock-soars-on-trump-tariff-hopes-and-pfizer-deal-200668094,"Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal Eli Lilly's stock surged 16% after potential positive developments with Trump administration tariff negotiations and manufacturing investments, with the company positioned to potentially avoid pharmaceutical import tariffs."
2025-10-07 13:30:00+00:00,https://www.fool.com/investing/2025/10/07/down-50-should-you-buy-the-dip-on-pfizer/?source=iedfolrf0000001,"Down 50%, Should You Buy the Dip on Pfizer? Pfizer is experiencing stock volatility after COVID-19 pandemic gains, facing patent cliffs for key drugs. The company is taking strategic steps like acquiring Metsera for a weight loss drug and negotiating drug pricing agreements to improve its long-term prospects."
2025-10-07 14:06:00+00:00,https://www.fool.com/investing/2025/10/07/the-no-1-investing-mistake-to-avoid-if-washington/?source=iedfolrf0000001,"The No. 1 Investing Mistake to Avoid As Washington Grinds to a Halt Investors should avoid making long-term investment decisions based on short-term events like government shutdowns, as emotional reactions can lead to poor financial choices. Understanding behavioral finance and maintaining a consistent investment strategy is crucial."
2025-10-08 14:15:00+00:00,https://www.fool.com/investing/2025/10/08/healthcare-stocks-are-rising-here-are-2-with-even/?source=iedfolrf0000001,"Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead Two innovative biotech companies, CRISPR Therapeutics and BioNTech, show significant potential for growth through promising drug pipelines and breakthrough medical technologies in gene editing and oncology."
2025-10-09 10:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/09/3163956/0/en/Zymeworks-Appoints-Dr-Adam-Schayowitz-as-Acting-Chief-Development-Officer.html,"Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer Zymeworks has appointed Dr. Adam Schayowitz as Acting Chief Development Officer, leveraging his extensive oncology drug development experience to advance the company's therapeutic pipeline and strategic partnerships."
2025-10-09 11:30:00+00:00,https://www.fool.com/investing/2025/10/09/watch-out-eli-lilly-this-pharma-giant-is-gunning/?source=iedfolrf0000001,"Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market Roche is entering the competitive GLP-1 weight loss drug market with its injectable drug CT-388, challenging Eli Lilly's current market leadership in obesity treatments."
2025-10-10 07:18:00+00:00,https://www.fool.com/investing/2025/10/10/heres-how-this-pharmaceutical-giant-is-protecting/?source=iedfolrf0000001,"Here's How This Pharmaceutical Giant Is Protecting Itself From President Trump's Tariffs. Should It Matter to Investors? Pfizer became the first pharmaceutical company to agree to most-favored-nation pricing with the Trump administration, receiving a three-year tariff grace period in exchange for investing in U.S. manufacturing and potentially creating a new direct sales platform."
2025-10-10 13:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/10/3164871/0/en/Molecule-Therapeutics-Market-Size-Companies-and-Emerging-Technologies-Insight-Towards-Healthcare.html,"Molecule Therapeutics Market Size, Companies and Emerging Technologies Insight – Towards Healthcare The global molecule therapeutics market is expected to experience substantial growth between 2024 and 2034, driven by advancements in precision medicine, targeted therapies, and personalized treatment approaches. North America leads the market, while Asia-Pacific shows the fastest growth potential."
2025-10-12 18:28:00+00:00,https://www.fool.com/investing/2025/10/12/4-dividend-stocks-to-double-up-on-right-now-includ/?source=iedfolrf0000001,"4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer The article highlights four dividend stocks that offer attractive investment opportunities: Enbridge, Pfizer, United Parcel Service, and Verizon Communications, each with unique strengths and high dividend yields."
2025-10-13 10:10:00+00:00,https://www.fool.com/investing/2025/10/13/drug-stocks-just-had-their-best-week-in-2-decades/?source=iedfolrf0000001,"Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? Pharmaceutical stocks experienced significant gains after the Trump administration delayed potential drug import tariffs, with major drugmakers striking deals to invest in U.S. manufacturing and avoid potential 100% tariffs."
2025-10-13 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/13/3165426/0/en/Arvinas-to-Present-Data-from-the-Vepdegestrant-Clinical-Development-Program-at-the-2025-European-Society-for-Medical-Oncology-ESMO-Congress.html,"Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress Arvinas will present new clinical data for vepdegestrant, an investigational PROTAC estrogen receptor degrader, at the 2025 ESMO Congress, highlighting patient-reported outcomes and potential treatments for ER+/HER2- breast cancer."
2025-10-13 14:15:00+00:00,https://www.fool.com/investing/2025/10/13/down-44-should-you-buy-the-dip-on-viking-therapeut/?source=iedfolrf0000001,"Down 44%, Should You Buy the Dip on Viking Therapeutics? Viking Therapeutics is developing promising weight loss drug candidates (VK2735) in injectable and oral forms, showing potential to compete in the rapidly growing $100 billion weight loss drug market. The company's clinical trials demonstrate significant weight loss percentages, making it an attractive investment opportunity despite competitive risks."
2025-10-14 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/14/3166002/0/en/Traws-Pharma-Doses-First-Patient-with-Ratutrelvir-in-Phase-2-COVID-Studies-Expects-Results-by-Year-End-2025.html,"Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 Traws Pharma initiated Phase 2 clinical trials for ratutrelvir, a ritonavir-free COVID-19 treatment, comparing its safety and efficacy against PAXLOVID®. The company expects to report trial results by year-end 2025, targeting potential improvements in COVID treatment."
2025-10-14 17:37:12+00:00,https://www.benzinga.com/news/health-care/25/10/48207253/pfizer-seeks-expanded-use-approval-for-breast-cancer-drug,"Pfizer Seeks Expanded Use Approval For Breast Cancer Drug Pfizer announced positive clinical trial results for Tukysa, a breast cancer drug targeting HER2+ metastatic breast cancer. The trial demonstrated significant improvement in progression-free survival and seeks expanded treatment approval."
2025-10-15 20:08:45+00:00,https://www.fool.com/investing/2025/10/15/why-moderna-might-be-a-one-hit-wonder/?source=iedfolrf0000001,"Why Moderna Might Be a One-Hit Wonder Moderna, once valued at $195 billion during the pandemic, has seen dramatic revenue decline from its COVID-19 vaccine. With only $3.1 billion in trailing revenue and significant operating losses, the company is banking on a promising personalized cancer vaccine developed with Merck."
2025-10-16 12:12:00+00:00,https://www.fool.com/investing/2025/10/16/a-once-in-a-decade-investment-opportunity-1-pharma/?source=iedfolrf0000001,"A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years Pfizer is addressing recent challenges by developing new medicines, expanding its pipeline, reducing expenses, and negotiating tariff exemptions. Despite past underperformance, the company shows potential for future growth with promising weight management drug acquisitions and a strong dividend yield."
2025-10-17 15:23:29+00:00,https://www.fool.com/coverage/filings/2025/10/17/qsm-asset-management-dumps-36-000-whirlpool-whr-shares-in-q3-2025/?source=iedfolrf0000001,"QSM Asset Management Dumps 36,000 Whirlpool (WHR) Shares in Q3 2025 QSM Asset Management sold 35,844 Whirlpool shares in Q3 2025, reducing its stake from over 7% to 2.2% of its assets under management, potentially due to dividend cuts and uncertainty about housing market recovery."
2025-10-17 16:43:32+00:00,https://www.benzinga.com/news/health-care/25/10/48280779/uk-health-agency-recommends-gsk-backed-viiv-healthcares-hiv,"UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment The UK's National Institute for Health and Care Excellence (NICE) recommended ViiV Healthcare's Apretude, an injectable HIV pre-exposure prophylaxis (PrEP) treatment, which offers bi-monthly protection and shows high patient and healthcare provider preference."
